<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Biochem Soc Trans</journal-id><journal-id journal-id-type="iso-abbrev">Biochem Soc Trans</journal-id><journal-id journal-id-type="pmc-domain-id">671</journal-id><journal-id journal-id-type="pmc-domain">portlandopen</journal-id><journal-id journal-id-type="publisher-id">BST</journal-id><journal-title-group><journal-title>Biochemical Society Transactions</journal-title></journal-title-group><issn pub-type="ppub">0300-5127</issn><issn pub-type="epub">1470-8752</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Portland Press Open Access</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8589429</article-id><article-id pub-id-type="pmcid-ver">PMC8589429.1</article-id><article-id pub-id-type="pmcaid">8589429</article-id><article-id pub-id-type="pmcaiid">8589429</article-id><article-id pub-id-type="pmid">34495299</article-id><article-id pub-id-type="doi">10.1042/BST20210766</article-id><article-id pub-id-type="publisher-id">BST-49-2411</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category"><subject>Chemical Biology</subject><subject>Glycobiology</subject><subject>Microbiology</subject><subject>Therapeutics &amp; Molecular Medicine</subject></subj-group><subj-group subj-group-type="heading"><subject>Review Articles</subject></subj-group></article-categories><title-group><article-title>Semi- and fully synthetic carbohydrate vaccines against pathogenic bacteria: recent developments</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zas&#322;ona</surname><given-names initials="ME">Magdalena E.</given-names></name><xref rid="af1" ref-type="aff"/><xref rid="af2" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Downey</surname><given-names initials="AM">A. Michael</given-names></name><xref rid="af1" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Seeberger</surname><given-names initials="PH">Peter H.</given-names></name><xref rid="af1" ref-type="aff"/><xref rid="af2" ref-type="aff"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6310-2579</contrib-id><name name-style="western"><surname>Moscovitz</surname><given-names initials="O">Oren</given-names></name><xref rid="af1" ref-type="aff"/><xref rid="af2" ref-type="aff"/><xref rid="cor1" ref-type="corresp"/></contrib></contrib-group><aff id="af1"><label>1</label>Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany</aff><aff id="af2"><label>2</label>Institute of Chemistry and Biochemistry, Freie Universit&#228;t Berlin, Berlin, Germany</aff><author-notes><corresp id="cor1"><bold>Correspondence:</bold> Oren Moscovitz (<email>Oren.Moscovitz@mpikg.mpg.de</email>)</corresp></author-notes><pub-date pub-type="ppub"><day>1</day><month>11</month><year>2021</year></pub-date><pub-date pub-type="epub"><day>8</day><month>9</month><year>2021</year></pub-date><volume>49</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">393716</issue-id><fpage>2411</fpage><lpage>2429</lpage><history><date date-type="received"><day>2</day><month>6</month><year>2021</year></date><date date-type="rev-recd"><day>11</day><month>8</month><year>2021</year></date><date date-type="accepted"><day>16</day><month>8</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>09</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>18</day><month>11</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2021-11-19 00:16:39.650"><day>19</day><month>11</month><year>2021</year></date></event></pub-history><permissions><copyright-statement>&#169; 2021 The Author(s)</copyright-statement><copyright-year>2021</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CC BY)</ext-link>. Open access for this article was enabled by the participation of Max Planck Digital Library in an all-inclusive Read &amp; Publish pilot with Portland Press and the Biochemical Society under a transformative agreement with Max Planck Digital Library.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="BST-49-2411.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="BST-49-2411.pdf"/><abstract><p>The importance of vaccine-induced protection was repeatedly demonstrated over the last three decades and emphasized during the recent COVID-19 pandemic as the safest and most effective way of preventing infectious diseases. Vaccines have controlled, and in some cases, eradicated global viral and bacterial infections with high efficiency and at a relatively low cost. Carbohydrates form the capsular sugar coat that surrounds the outer surface of human pathogenic bacteria. Specific surface-exposed bacterial carbohydrates serve as potent vaccine targets that broadened our toolbox against bacterial infections. Since first approved for commercial use, antibacterial carbohydrate-based vaccines mostly rely on inherently complex and heterogenous naturally derived polysaccharides, challenging to obtain in a pure, safe, and cost-effective manner. The introduction of synthetic fragments identical with bacterial capsular polysaccharides provided well-defined and homogenous structures that resolved many challenges of purified polysaccharides. The success of semisynthetic glycoconjugate vaccines against bacterial infections, now in different phases of clinical trials, opened up new possibilities and encouraged further development towards fully synthetic antibacterial vaccine solutions. In this mini-review, we describe the recent achievements in semi- and fully synthetic carbohydrate vaccines against a range of human pathogenic bacteria, focusing on preclinical and clinical studies.</p></abstract><kwd-group kwd-group-type="author"><kwd>antibacterial vaccines</kwd><kwd>bacteria</kwd><kwd>capsular polysaccharides</kwd><kwd>carbohydrates</kwd><kwd>synthetic carbohydrate</kwd><kwd>vaccines</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Over their 200-year history, vaccines have become the most cost-effective medical intervention to prevent morbidity and mortality worldwide. Mainly due to developments of the last 50 years, vaccines have improved human health enormously. Vaccines have controlled and, in some cases, eradicated many viral (smallpox, measles, polio) and bacterial (diphtheria, tetanus) infectious diseases.</p><p>Carbohydrates, present on the outermost surface of all cells, can serve as potent antigenic targets for vaccine design much like protein antigens. Moreover, carbohydrate-based vaccines can broaden the molecular palette of potential targets to combat a wide range of pathogens [<xref rid="BST-49-2411C1" ref-type="bibr">1</xref>]. Traditionally, carbohydrate-based vaccines have resulted from purified carbohydrate antigens from cultivated pathogens; however, carbohydrate-based vaccines isolated from pathogen cultures are of heterogeneous composition, may contain impurities, and necessitate a complicated manufacturing process.</p><p>These problems have been solved by the introduction of synthetic carbohydrate-based vaccines. Since the introduction of the first commercialized synthetic carbohydrate-based vaccine Quimi-Hib (CIGB, Cuba) to the market in 2004 [<xref rid="BST-49-2411C2" ref-type="bibr">2</xref>], this field has burgeoned. Improvements in the chemical synthesis of carbohydrates, especially due to the introduction of automated glycan assembly, have facilitated access to these crucial synthetic carbohydrate epitopes.</p><p>This mini-review describes the most significant developments in fully and semisynthetic antibacterial carbohydrate-based vaccines since 2016. We focus on preclinical and clinical studies of vaccines targeting <italic toggle="yes">Streptococcus pneumoniae</italic>, <italic toggle="yes">Streptococcus</italic> Groups A and B, <italic toggle="yes">Neisseria meningitis</italic>, <italic toggle="yes">Shigella flexneri</italic>, <italic toggle="yes">Salmonella enterica</italic>, <italic toggle="yes">Vibrio cholerae</italic>, and <italic toggle="yes">Burkholderia pseudomallei</italic> and <italic toggle="yes">mallei</italic>. We refer the interested reader to a recent comprehensive review that provides an in-depth examination of synthetic-carbohydrate technology and its use against bacterial infections [<xref rid="BST-49-2411C3" ref-type="bibr">3</xref>].</p></sec><sec id="s2"><title>The composition of carbohydrate-based vaccines: carrier proteins and adjuvants</title><p>The main obstacle in the design of carbohydrate-based vaccines is the poor immunogenicity of pure carbohydrate antigens in high-risk groups, such as infants and the elderly [<xref rid="BST-49-2411C1" ref-type="bibr">1</xref>]. Carbohydrate-based vaccines against infectious diseases are immunogenic and protective in older children and adults; however, stimulation of the immune system triggered by glycans is not efficient in the first years of life [<xref rid="BST-49-2411C4" ref-type="bibr">4&#8211;6</xref>]. Carbohydrate antigens do not induce T-cell-dependent immunological responses, which results in a lack of immunological memory to the pathogens. The primary immune response to carbohydrate antigens results in the production of low-affinity and short-lived immunoglobulin (Ig) M antibodies. Moreover, repeated exposure to the antigen does not improve the immunological response. The finding by Avery and Goebel almost a century ago that immunogenicity of polysaccharides is enhanced by coupling to a carrier protein was an essential milestone in vaccine history that led eventually to today's commercial glycoconjugate vaccines [<xref rid="BST-49-2411C7" ref-type="bibr">7</xref>]. Glycoconjugate vaccines contain carbohydrate antigens conjugated to a carrier protein. In contrast with non-conjugated carbohydrate antigens, glycoconjugates are processed by antigen-presenting cells and presented by the major histocompatibility complex (MHC) class II molecules to T cells. MHC-II presentation then activates both B- and T-cell immune responses that lead to IgM-to-IgG class switching, differentiation of glycan-specific memory B cells, and long-lived T-cell memory [<xref rid="BST-49-2411C8" ref-type="bibr">8</xref>,<xref rid="BST-49-2411C9" ref-type="bibr">9</xref>] (<xref rid="BST-49-2411F1" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="BST-49-2411F1" orientation="portrait"><label>Figure&#160;1.</label><caption><title>T cells-dependent and independent activation of B cells by synthetic oligosaccharides.</title><p>(<bold>A</bold>) Synthetic oligosaccharides bind B-cell receptors (BCRs) but cannot be presented by the MHCII complexes to T-cell receptors (TCRs). B cell uptake of oligosaccharides launches plasma cells development and low-affinity antibody production. (<bold>B</bold>) Synthetic glycoconjugates are composed of oligosaccharides coupled with a carrier protein. Glycoconjugates internalization and processing by antigen-presenting cells (APCs) enables the presentation of glycopeptides on the MHCII complexes. MHCII binding and activation of TCRs result in memory B cells formation and high affinity IgGs development.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BST-49-2411-g0001.jpg"/></fig><p>Pioneering work by the Robbins and Schneerson team at NIH led to the first polysaccharide conjugate vaccine against <italic toggle="yes">Haemophilus influenzae</italic> type b (Hib) [<xref rid="BST-49-2411C10" ref-type="bibr">10</xref>] composed of a carbohydrate moiety conjugated to a carrier protein, licensed between 1987 and 1990 [<xref rid="BST-49-2411C11" ref-type="bibr">11</xref>]. There are currently five carrier proteins used in licensed conjugate vaccines and shown in clinical trials to increase glycoconjugate vaccines immunogenicity: (1) diphtheria toxoid (DT); (2) the genetically modified cross-reacting material of diphtheria toxin (CRM)<sub>197</sub>; (3) tetanus toxoid (TT); (4) outer membrane protein complex (OMPC) from serogroup B meningococcus; (5) and <italic toggle="yes">Haemophilus influenzae</italic> protein D (HiD). The main differences between the carrier proteins are the maximal number of conjugated carbohydrates and the type of antibodies and immune response they elicit (for a recent comprehensive review, see [<xref rid="BST-49-2411C11" ref-type="bibr">11</xref>].</p><p>Some vaccines either in the developmental phase or already licensed may additionally contain adjuvants. Adjuvants increase the uptake of target antigens, including carbohydrate antigens, which results in better immunogenicity of the vaccine formulation. Many external adjuvants have been developed to augment the immunogenicity of the experimental and clinical vaccines, including mineral salts, liposome emulsions, inactivated bacteria, protein toxins, immune cell receptors activating ligands, and aluminium salts as adjuvants [<xref rid="BST-49-2411C12" ref-type="bibr">12</xref>].</p></sec><sec id="s3"><title>Traditional carbohydrate-based vaccines</title><p>Most carbohydrate-based vaccines consist of native carbohydrate antigens that induce an effective immune response against the respective pathogens. Despite their tremendous efficacy, native carbohydrate vaccines face several drawbacks. First, the inherent structural heterogeneity of native carbohydrates may result in batch-to-batch variation and efficiency of the glycoconjugate vaccines. Cell impurities, such as proteins and nucleic acids, may pose a risk when used for immunization. As a result, purifying native carbohydrates involves complicated, expensive, and time-consuming steps required for a successful and safe vaccine manufacturing process [<xref rid="BST-49-2411C13" ref-type="bibr">13</xref>,<xref rid="BST-49-2411C14" ref-type="bibr">14</xref>]. Culturing large numbers of pathogens is another limiting factor with safety concerns for personnel and the environment. Different pathogens cannot be cultivated at a sufficient scale, or it is impossible to cultivate them in a scalable setting for manufacturing purposes. The presence of several functional groups with the potential to generate a link with the carrier protein may result in uncontrolled and unreproducible conjugation that may alter the specificity, level, and type of the desired immune response [<xref rid="BST-49-2411C15" ref-type="bibr">15</xref>]. Thus, vaccines based on cultivated pathogens require high-quality standards for formulations, which relates to difficulties in obtaining regulatory approvals [<xref rid="BST-49-2411C16" ref-type="bibr">16</xref>]. All carbohydrate-based vaccines currently approved by the FDA, which are exclusively traditionally obtained, are listed in <xref rid="BST-49-2411TB1" ref-type="table">Table 1</xref>.</p><table-wrap position="float" id="BST-49-2411TB1" orientation="portrait"><label>Table&#160;1</label><caption><title>Carbohydrate-based vaccines approved by the FDA</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Antigen</th><th align="left" rowspan="1" colspan="1">Indications</th><th align="left" rowspan="1" colspan="1">Trade name</th><th align="left" rowspan="1" colspan="1">Manufacturer</th><th align="left" rowspan="1" colspan="1">Carrier protein</th><th align="left" rowspan="1" colspan="1">Adjuvant</th><th align="left" rowspan="1" colspan="1">Age approval age</th></tr></thead><tbody><tr><td rowspan="5" colspan="1"><italic toggle="yes">Haemophilus influenzae</italic> type b; CPS (polyribosyl-ribitol-phosphate)</td><td rowspan="3" colspan="1">invasive disease caused by <italic toggle="yes">Heamophilus influenzae</italic> type b</td><td rowspan="1" colspan="1">HIBERIX</td><td rowspan="1" colspan="1">GlaxoSmithKline Biologicals</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">children 6 weeks&#8211;4 years</td></tr><tr><td rowspan="1" colspan="1">ActHIB</td><td rowspan="1" colspan="1">Sanofi Pasteur</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">children 2 months&#8211;5 years</td></tr><tr><td rowspan="1" colspan="1">Liquid PedvaxHIB</td><td rowspan="1" colspan="1">Merck Sharp &amp; Dohme</td><td rowspan="1" colspan="1">OMPC</td><td rowspan="1" colspan="1">amorphous aluminium hydroxyphosphate sulfate</td><td rowspan="1" colspan="1">children 2 months&#8211;5 years</td></tr><tr><td rowspan="1" colspan="1">diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease caused by <italic toggle="yes">Heamophilus influenzae</italic> type b</td><td rowspan="1" colspan="1">Pentacel</td><td rowspan="1" colspan="1">Sanofi Pasteur</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1">aluminium phosphate</td><td rowspan="1" colspan="1">children 6 weeks&#8211;4 years</td></tr><tr><td rowspan="1" colspan="1">diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease caused by <italic toggle="yes">Heamophilus influenzae</italic> type b</td><td rowspan="1" colspan="1">VAXELIS</td><td rowspan="1" colspan="1">MCM Vaccine</td><td rowspan="1" colspan="1">OMPC</td><td rowspan="1" colspan="1">aluminium salts (various)</td><td rowspan="1" colspan="1">children 6 weeks&#8211;4 years</td></tr><tr><td rowspan="4" colspan="1"><italic toggle="yes">Neisseria meningitidis</italic> serogroups A, C, Y and W-135 (Menactra, Menveo, Menomune-A/C/Y/W-135) or serogroup W (MenQuadfi); CPS</td><td rowspan="4" colspan="1">invasive meningococcal disease caused by <italic toggle="yes">Neisseria meningitidis</italic> serogroups A, C, Y, and W-135 or W</td><td rowspan="1" colspan="1">Menactra</td><td rowspan="1" colspan="1">Sanofi Pasteur</td><td rowspan="1" colspan="1">DT</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">9 months&#8211;55 years</td></tr><tr><td rowspan="1" colspan="1">MENVEO</td><td rowspan="1" colspan="1">GlaxoSmithKline Biologicals SA</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">2 months&#8211;55 years</td></tr><tr><td rowspan="1" colspan="1">Menomune-A/C/Y/W-135</td><td rowspan="1" colspan="1">Sanofi Pasteur</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">&#8805;2 years</td></tr><tr><td rowspan="1" colspan="1">MenQuadfi</td><td rowspan="1" colspan="1">Sanofi Pasteur</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">&#8805;2 years</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">Salmonella enterica</italic> serovar Typhi; cell surface Vi polysaccharide</td><td rowspan="1" colspan="1">typhoid fever caused by <italic toggle="yes">Salmonella enterica</italic> serovar Typhi</td><td rowspan="1" colspan="1">Typhim Vi</td><td rowspan="1" colspan="1">Sanofi Pasteur</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">&#8805;2 years</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">Streptococcus pneumoniae</italic> serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F; CPS</td><td rowspan="1" colspan="1">invasive disease caused by <italic toggle="yes">Streptococcus pneumoniae</italic> serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F</td><td rowspan="1" colspan="1">Prevnar 13</td><td rowspan="1" colspan="1">Wyeth Pharmaceuticals</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">aluminium phosphate</td><td rowspan="1" colspan="1">children 6 weeks-5 years; children 6 years-17 years; adults &#8805;18 years</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">Streptococcus pneumoniae</italic> serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F; CPS</td><td rowspan="1" colspan="1">invasive disease caused by <italic toggle="yes">Streptococcus pneumoniae</italic> serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F</td><td rowspan="1" colspan="1">PNEUMOVAX 23</td><td rowspan="1" colspan="1">Merck &amp; Co.</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">&#8805;50 years and persons &#8805;2 years who are at increased risk of pneumococcal disease</td></tr></tbody></table><table-wrap-foot><p>Currently, all the approved vaccines are traditionally obtained, consisting of carbohydrate antigens purified from isolated antigens.</p><p>This table was adopted from the complete list of &#8216;Vaccines Licensed for Use in the United States' provided by the US Food and Drug Administration website (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/" ext-link-type="uri">https://www.fda.gov/</ext-link>). CPS: capsular polysaccharide.</p><p>Content current as of: March 8, 2021.</p></table-wrap-foot></table-wrap><sec id="s3a"><title>Synthetic carbohydrate-based vaccines</title><p>In contrast with traditional carbohydrate-based vaccines, synthetic carbohydrate formulations are highly reproducible with homogenous, well-defined composition. Their highly defined molecular carbohydrate structure may potentially lower the costs of the vaccine design and eliminate the costly cold chain, which is especially challenging to maintain in hot developing countries [<xref rid="BST-49-2411C13" ref-type="bibr">13</xref>,<xref rid="BST-49-2411C17" ref-type="bibr">17</xref>]. Synthetic carbohydrate-based vaccines can be divided into two categories: semisynthetic and fully synthetic.</p><sec id="s3a1"><title>Semisynthetic carbohydrate-based vaccines</title><p>Semisynthetic carbohydrate-based vaccines are comprised of mono- or multivalent glycans conjugated to a carrier protein, and an adjuvant is co-administered as a separate molecule (<xref rid="BST-49-2411F2" ref-type="fig">Figure 2A</xref>) [<xref rid="BST-49-2411C3" ref-type="bibr">3</xref>,<xref rid="BST-49-2411C18" ref-type="bibr">18</xref>]. One of the most commonly used carrier proteins is CRM<sub>197.</sub> Although semisynthetic vaccines comprised of a conventional peptide/protein carrier are still under development, the carbohydrate moiety in emerging semisynthetic vaccine candidates can be conjugated to novel carriers, for example, virus-like particles such as bacteriophage Q&#946;.</p><fig position="float" id="BST-49-2411F2" orientation="portrait"><label>Figure&#160;2.</label><caption><title>Synthetic carbohydrate-based vaccines.</title><p>(<bold>A</bold>) Semisynthetic and (<bold>B</bold>) fully synthetic vaccine strategies.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BST-49-2411-g0002.jpg"/></fig><p>Superficially, the selection of the chain of atoms connecting the immunogenic glycan to the carrier protein may seem trivial; however, to synthetic chemists, this &#8216;linker' is especially important: it must usually contain hydrophilic scaffolding, such as ether and/or amide functional groups, to ensure solubility while surviving multiple synthetic steps (<xref rid="BST-49-2411F2" ref-type="fig">Figure 2A</xref>).</p></sec><sec id="s3a2"><title>Fully synthetic carbohydrate-based vaccines</title><p>In fully synthetic carbohydrate-based vaccines, the carbohydrate moiety conjugated to the synthetic carrier, such as a glycolipid, synthetic peptide, or a nanoparticle, is combined with different adjuvants all to form one (macro)molecule (<xref rid="BST-49-2411F2" ref-type="fig">Figure 2B</xref>). Interestingly, even in the absence of a carrier protein, fully synthetic solutions based on glycolipids carrying liposomes, zwitterionic polysaccharides, or carbohydrate-based nanoparticles induce T cell-dependent response through different mechanisms successfully [<xref rid="BST-49-2411C3" ref-type="bibr">3</xref>,<xref rid="BST-49-2411C18" ref-type="bibr">18</xref>,<xref rid="BST-49-2411C19" ref-type="bibr">19</xref>]. Although co-localization of the elements in the same molecule triggers a more potent antibody response than in the case of semisynthetic vaccines, none of the fully synthetic vaccine formulations is currently marketed [<xref rid="BST-49-2411C20" ref-type="bibr">20</xref>]. Since 2016, only one self-adjuvating fully synthetic vaccine for <italic toggle="yes">Neisseria meningitis</italic> Group C includes the glycolipid monophosphoryl lipid A (MPLA), a modified form of lipid A, the lipophilic constituent of bacterial lipopolysaccharides [<xref rid="BST-49-2411C21" ref-type="bibr">21</xref>].</p><p>We turn our attention now to the strides made in synthetic antibacterial vaccines.</p></sec></sec></sec><sec id="s4"><title>Antibacterial semisynthetic carbohydrate-based vaccines</title><p>To make polysaccharide vaccines more reproducible and cost effective, the nature-derived bacterial polysaccharides are replaced with synthetic structures to make semisynthetic vaccines. Below, we describe semisynthetic and one fully synthetic vaccine candidates in the discovery phase and in clinical trials aimed at improving currently existing antibacterial vaccines or at elucidating new vaccine candidates for combating bacterial infections. All semi- and fully synthetic antibacterial glycoconjugate vaccine candidates described in this mini-review are divided based on the bacteria they target and listed in <xref rid="BST-49-2411TB2" ref-type="table">Table 2</xref> and <xref rid="BST-49-2411TB3" ref-type="table">Table 3</xref> (Gram-positive and Gram-negative bacteria, respectively).</p><table-wrap position="float" id="BST-49-2411TB2" orientation="portrait"><label>Table&#160;2</label><caption><title>Semisynthetic glycoconjugate vaccine candidates of selected Gram-positive bacteria</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Bacterium and serotype (ST)</th><th align="left" rowspan="1" colspan="1">Type of glycan</th><th align="left" rowspan="1" colspan="1">Saccharide (identified as most promising)</th><th align="left" rowspan="1" colspan="1">Approach</th><th align="left" rowspan="1" colspan="1">Carrier protein</th><th align="left" rowspan="1" colspan="1">Preclinical evaluation</th><th align="left" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><italic toggle="yes">S. pneumoniae</italic> pentavalent semisynthetic glycoconjugate vaccine ST2, ST3, ST5, ST8, ST14</td><td rowspan="16" colspan="1">CPS</td><td rowspan="1" colspan="1">oligosaccharides depending on the STs</td><td rowspan="20" colspan="1">Semi-synthetic</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">rabbits</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C35" ref-type="bibr">35</xref>]</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">S. pneumoniae</italic> ST1</td><td rowspan="1" colspan="1">trisaccharide</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">rabbits</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C36" ref-type="bibr">36</xref>]</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">S. pneumoniae</italic> ST2</td><td rowspan="1" colspan="1">hexasaccharide</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">mice</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C26" ref-type="bibr">26</xref>]</td></tr><tr><td rowspan="4" colspan="1"><italic toggle="yes">S. pneumoniae</italic> ST3</td><td rowspan="1" colspan="1">tetrasaccharide</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">mice</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C27" ref-type="bibr">27</xref>]</td></tr><tr><td rowspan="1" colspan="1">tetrasaccharide</td><td rowspan="1" colspan="1">BSA</td><td rowspan="1" colspan="1">mice &amp; rabbits</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C37" ref-type="bibr">37</xref>]</td></tr><tr><td rowspan="1" colspan="1">hexasacchride</td><td rowspan="2" colspan="1">TT</td><td rowspan="1" colspan="1">mice</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C40" ref-type="bibr">40</xref>]</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">rabbit</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C41" ref-type="bibr">41</xref>]</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">S. pneumoniae</italic> ST3 and ST14</td><td rowspan="1" colspan="1">tetrasaccharides</td><td rowspan="1" colspan="1">bacteriophage Q&#946;</td><td rowspan="1" colspan="1">mice</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C48" ref-type="bibr">48</xref>]</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">S. pneumoniae</italic> ST4</td><td rowspan="1" colspan="1">tetrasaccharide</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">mice</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C28" ref-type="bibr">28</xref>]</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">S. pneumoniae</italic> ST5</td><td rowspan="1" colspan="1">oligosaccharides</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">rabbits</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C34" ref-type="bibr">34</xref>]</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">S. pneumoniae</italic> ST8</td><td rowspan="1" colspan="1">tetrasaccharide</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">rabbits</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C30" ref-type="bibr">30</xref>]</td></tr><tr><td rowspan="4" colspan="1"><italic toggle="yes">S. pneumoniae</italic> ST14</td><td rowspan="1" colspan="1">hexasaccharide</td><td rowspan="1" colspan="1">BSA</td><td rowspan="1" colspan="1">mice</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C42" ref-type="bibr">42</xref>]</td></tr><tr><td rowspan="1" colspan="1">hexasaccharide</td><td rowspan="1" colspan="1">BSA</td><td rowspan="1" colspan="1">mice</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C38" ref-type="bibr">38</xref>,<xref rid="BST-49-2411C39" ref-type="bibr">39</xref>]</td></tr><tr><td rowspan="1" colspan="1">tetrasaccharide</td><td rowspan="1" colspan="1">pneumococcal surface adhesin A</td><td rowspan="1" colspan="1">mice</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C45" ref-type="bibr">45</xref>]</td></tr><tr><td rowspan="1" colspan="1">repeating unit connected with aliphatic spacer</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">mice</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C47" ref-type="bibr">47</xref>]</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">S. pneumoniae</italic> ST19A and ST19F</td><td rowspan="1" colspan="1">chimeric antigen comprised of a repeating unit of ST19A and ST19F CPS each</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">rabbits</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C44" ref-type="bibr">44</xref>]</td></tr><tr><td rowspan="1" colspan="1">GAS various serotypes</td><td rowspan="2" colspan="1">cell-wall polysaccharide</td><td rowspan="1" colspan="1">branched oligosaccharides containing one, two and three repeating units of CPS</td><td rowspan="1" colspan="1">inactive mutant of group A streptococcal C5a peptidase (ScpA), ScpA193</td><td rowspan="1" colspan="1">mice</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C50" ref-type="bibr">50</xref>,<xref rid="BST-49-2411C51" ref-type="bibr">51</xref>]</td></tr><tr><td rowspan="1" colspan="1">GAS various serotypes</td><td rowspan="1" colspan="1">oligorhamnoside fragments</td><td rowspan="1" colspan="1">gold nanoparticles</td><td rowspan="1" colspan="1">competitive ELISA</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C52" ref-type="bibr">52</xref>]</td></tr><tr><td rowspan="1" colspan="1">GBS type Ia</td><td rowspan="2" colspan="1">CPS</td><td rowspan="1" colspan="1">a dimer composed of two pentasaccharides and its corresponding monomer</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">mice</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C53" ref-type="bibr">53</xref>]</td></tr><tr><td rowspan="1" colspan="1">GBS type III</td><td rowspan="1" colspan="1">hexasaccharide</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">competitive ELISA &amp; mice</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C54" ref-type="bibr">54&#8211;56</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="BST-49-2411TB3" orientation="portrait"><label>Table&#160;3</label><caption><title>Semisynthetic and fully synthetic glycoconjugate vaccine candidates against selected Gram-negative bacteria</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Bacteria and serotype</th><th align="left" rowspan="1" colspan="1">Type of glycan</th><th align="left" rowspan="1" colspan="1">Saccharide</th><th align="left" rowspan="1" colspan="1">Approach</th><th align="left" rowspan="1" colspan="1">Carrier protein or (molecule)</th><th align="left" rowspan="1" colspan="1">(Pre)clinical evaluation</th><th align="left" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><italic toggle="yes">N. meningitidis</italic> serogroup A</td><td rowspan="5" colspan="1">CPS</td><td rowspan="1" colspan="1">oligosaccharide</td><td rowspan="2" colspan="1">Semi-synthetic</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1">ELISA</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C65" ref-type="bibr">65</xref>]</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">N. meningitidis</italic> serogroup A</td><td rowspan="1" colspan="1">oligosaccharide</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">mice</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C64" ref-type="bibr">64</xref>]</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">N. meningitidis</italic> serogroup C</td><td rowspan="1" colspan="1">oligosaccharides and glycolipids</td><td rowspan="1" colspan="1">fully synthetic, self- adjuvanting</td><td rowspan="1" colspan="1">(MPLA)</td><td rowspan="1" colspan="1">mice</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C21" ref-type="bibr">21</xref>]</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">N. meningitidis</italic> serogroup C</td><td rowspan="1" colspan="1">oligosaccharide</td><td rowspan="5" colspan="1">Semi-synthetic</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1">mice</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C67" ref-type="bibr">67</xref>]</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">N. meningitidis</italic> serogroup X</td><td rowspan="1" colspan="1">oligosaccharide</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">mice</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C63" ref-type="bibr">63</xref>]</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">N. meningitidis</italic> various strains and other pathogenic bacteria</td><td rowspan="1" colspan="1">LPS</td><td rowspan="1" colspan="1">oligosaccharide</td><td rowspan="1" colspan="1">DT</td><td rowspan="1" colspan="1">rabbits</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C68" ref-type="bibr">68</xref>]</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">S. flexneri</italic> 2a</td><td rowspan="2" colspan="1">O-polysaccharide of LPS</td><td rowspan="1" colspan="1">oligosaccharide</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1">mice</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C70" ref-type="bibr">70</xref>]</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">S. flexneri</italic> 2a</td><td rowspan="1" colspan="1">oligosaccharide</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1">Clinical trial, Phase 1, Phase 2 currently recruiting</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C71" ref-type="bibr">71</xref>]</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhi</td><td rowspan="1" colspan="1">Vi CPS</td><td rowspan="1" colspan="1">high molecular weight polysaccharide</td><td rowspan="1" colspan="1">only polysaccharide antigen</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">molecular modeling</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C74" ref-type="bibr">74</xref>]</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Enteritidis</td><td rowspan="4" colspan="1">O-polysaccharide of LPS</td><td rowspan="1" colspan="1">oligosaccharide</td><td rowspan="7" colspan="1">Semi-synthetic</td><td rowspan="1" colspan="1">bacteriophage Q&#946;</td><td rowspan="1" colspan="1">mice</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C78" ref-type="bibr">78</xref>]</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Paratyphi A</td><td rowspan="1" colspan="1">oligosaccharide</td><td rowspan="1" colspan="1">bacteriophage Q&#946;</td><td rowspan="1" colspan="1">mice</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C79" ref-type="bibr">79</xref>]</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">V. cholerae</italic> O139</td><td rowspan="1" colspan="1">oligosaccharide</td><td rowspan="1" colspan="1">BSA</td><td rowspan="1" colspan="1">none</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C84" ref-type="bibr">84</xref>]</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">V. cholerae</italic> O1 serotype Inaba</td><td rowspan="1" colspan="1">glycoclusters displaying oligosaccharides</td><td rowspan="1" colspan="1">BSA</td><td rowspan="1" colspan="1">ELISA</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C85" ref-type="bibr">85</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">B. pseudomallei</italic>
</td><td rowspan="1" colspan="1">CPS</td><td rowspan="1" colspan="1">oligosaccharide</td><td rowspan="1" colspan="1">Nontoxic H<sub>c</sub> domain of TT</td><td rowspan="1" colspan="1">mice</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C87" ref-type="bibr">87</xref>]</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">B. pseudomallei</italic> and <italic toggle="yes">mallei</italic></td><td rowspan="1" colspan="1">O-polysaccharide of LPS</td><td rowspan="1" colspan="1">disaccharide</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">mice</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C88" ref-type="bibr">88</xref>]</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">B. pseudomallei</italic> and <italic toggle="yes">mallei</italic></td><td rowspan="1" colspan="1">CPS</td><td rowspan="1" colspan="1">oligosaccharide</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">meliodosis patient sera</td><td rowspan="1" colspan="1">[<xref rid="BST-49-2411C89" ref-type="bibr">89</xref>]</td></tr></tbody></table></table-wrap><sec id="s4a"><title>
Streptococcus pneumoniae
</title><p>Infectious diseases caused by the bacterium <italic toggle="yes">Streptococcus pneumoniae (S. pneumoniae)</italic>, like pneumonia, septicemia, meningitis, and otitis media, are a global burden to medical systems and can be prevented by vaccination. Currently, over 90 serotypes (ST) of <italic toggle="yes">S. pneumoniae</italic> have been identified [<xref rid="BST-49-2411C22" ref-type="bibr">22</xref>]. There are currently three licensed pneumococcal conjugate vaccines: (1) Synflorix (GlaxoSmithKline Biologicals S.A., Belgium), a decavalent vaccine distributed in Europe [<xref rid="BST-49-2411C23" ref-type="bibr">23</xref>]; (2) Prevnar 13 (Wyeth Pharmaceuticals, Inc., PA, U.S.A.), a 13-valent vaccine distributed in Europe and the United States [<xref rid="BST-49-2411C24" ref-type="bibr">24</xref>]; (3) and a new decavalent pneumococcal conjugate vaccine, Pneumosil (Serum Institute of India, Ltd., India) [<xref rid="BST-49-2411C25" ref-type="bibr">25</xref>] launched in India at the end of 2020<xref rid="FN0001" ref-type="fn"><sup>1</sup></xref>
<fn id="FN0001"><p><sup>1</sup><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.seruminstitute.com/news_pneumosil_281220.php" ext-link-type="uri">https://www.seruminstitute.com/news_pneumosil_281220.php</ext-link></p></fn>. Conjugates of nature-derived CPSs connected with a number of production and safety difficulties can be exchanged by semisynthetic glycoconjugate compounds to improve efficiency and coverage of pneumococcal conjugate vaccines.</p><p>We have worked toward incorporating new synthetic carbohydrates into existing pneumococcal conjugate vaccines and identifying protective and/or minimal glycan epitopes (glycotopes) of currently licensed vaccine polysaccharides. Since 2016, we have identified immunogenic and protective glycotopes of five STs: (1) ST2 (26), (2) ST3 [<xref rid="BST-49-2411C27" ref-type="bibr">27</xref>], (3) ST4 [<xref rid="BST-49-2411C28" ref-type="bibr">28</xref>], (4) ST7F [<xref rid="BST-49-2411C29" ref-type="bibr">29</xref>], and (5) ST8 [<xref rid="BST-49-2411C30" ref-type="bibr">30</xref>] (<xref rid="BST-49-2411F2" ref-type="fig">Figure 2</xref>). In all cases, glycan arrays containing synthetic repeating-unit oligosaccharides from each respective ST were used to screen reference sera for antibodies. The selected synthetic oligosaccharides of ST2, ST3, ST4, and ST8 were conjugated to CRM<sub>197</sub> for in-depth immunological evaluation in animal models revealing that studies involving ST2 [<xref rid="BST-49-2411C26" ref-type="bibr">26</xref>] and ST3 [<xref rid="BST-49-2411C27" ref-type="bibr">27</xref>] elicited protective antibacterial immunity in mice; and ST8 [<xref rid="BST-49-2411C30" ref-type="bibr">30</xref>] in rabbits. The glycoconjugate candidate of ST4 [<xref rid="BST-49-2411C28" ref-type="bibr">28</xref>] was immunogenic in mice, but it had limited binding to the CPS from the respective serotype. Further analysis revealed the importance of terminal sugars in glycoconjugates for a successful immune response. Thus, the laboratory has proposed semisynthetic vaccine candidates containing relatively short synthetic oligosaccharides that may serve as promising alternatives to larger polysaccharide antigens from natural sources (<xref rid="BST-49-2411F3" ref-type="fig">Figure 3</xref>). Except for the above mentioned semisynthetic vaccine candidates, we published several syntheses of pneumococcal oligosaccharide antigens including: (1) ST9&#8197;V for better understanding of the importance of glycan modifications and further immunological evaluation [<xref rid="BST-49-2411C31" ref-type="bibr">31</xref>]; (2) the total synthesis of the ST12F hexasaccharide using a new linear approach [<xref rid="BST-49-2411C32" ref-type="bibr">32</xref>]; and (3) the first iterative automated glycan assembly of conjugation-ready ST3 capsular trisaccharide [<xref rid="BST-49-2411C33" ref-type="bibr">33</xref>]. A glycoconjugate containing stable synthetic oligosaccharide analogs of the ST5 CPS repeating unit prevents stability issues associated with the native CPSs that include rare carbohydrates [<xref rid="BST-49-2411C34" ref-type="bibr">34</xref>].</p><fig position="float" id="BST-49-2411F3" orientation="portrait"><label>Figure&#160;3.</label><caption><title>The structures of the immunogenic glycotopes in <italic toggle="yes">S. pneumoniae</italic> complete with a linker conjugated to CRM<sub>197</sub>.</title><p>Linkers, T-cell epitopes, and adjuvant are designated in blue, maroon, and orange, respectively, throughout this survey.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BST-49-2411-g0003.jpg"/></fig><p>Aiming to improve Synflorix and Prevnar 13 by synthetic glycoconjugates, we proposed a pentavalent semisynthetic glycoconjugate pneumococcal vaccine that includes the following STs: (1) ST2, ST8, that have not been included in currently marketed vaccines, and ST3 absent from Synflorix; (2) ST5, which suffers from low immunogenicity or production inconsistencies; and (3) ST14 that is present in both licensed vaccines&#8212;however, it is included to show that nonproblematic STs from natural sources can easily be exchanged by synthetic glycoconjugates. The proposed vaccine conjugated to CRM<sub>197</sub> elicited a robust, polysaccharide-specific antibody response compared with marketed vaccines, proving that synthetic oligosaccharides can be used in coformulation with Synflorix and Prevnar [<xref rid="BST-49-2411C35" ref-type="bibr">35</xref>]. Further endeavors have focused on ST1, which in Synflorix and Prevnar 13 induces low levels of functional antibodies. An unusual monosaccharide, 2-acetamido-4-amino-2,4,6-trideoxy-D-galactose (D-AAT), present in ST1 may be responsible for the reduced vaccine efficacy. Nonetheless, a semisynthetic glycoconjugate carrying D-AAT at the nonreducing end conjugated to the CRM<sub>197</sub> carrier protein elicited a strong immune response in rabbits, proving the immunological importance of D-AAT (<xref rid="BST-49-2411F4" ref-type="fig">Figure 4</xref>) [<xref rid="BST-49-2411C36" ref-type="bibr">36</xref>]. Thus, the feasibility of incorporating ST1 into a semisynthetic vaccine remains to be seen.</p><fig position="float" id="BST-49-2411F4" orientation="portrait"><label>Figure&#160;4.</label><caption><title>The structure of Streptococcus. pneumoniae glycotope D-AAT.</title><p>Capsular ST1 bearing the crucial, yet highly reactive, D-AAT [<xref rid="BST-49-2411C36" ref-type="bibr">36</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BST-49-2411-g0004.jpg"/></fig><p>The Nifantiev laboratory conducted intensive research on semisynthetic pneumococcal glycoconjugate vaccines. A comparative immunological study of synthetic oligosaccharides of the CPS repeating units of ST3 [<xref rid="BST-49-2411C37" ref-type="bibr">37</xref>] and ST14 [<xref rid="BST-49-2411C38" ref-type="bibr">38</xref>,<xref rid="BST-49-2411C39" ref-type="bibr">39</xref>] conjugated to bovine serum albumin (BSA) revealed that the optimal candidates for semisynthetic vaccines for both STs are tetrasaccharide ligands. Further immunological studies in mice revealed protective properties of both neoglycoconjugates. Nifantiev and coworkers compared glycotopes from di- to tetrasaccharides of ST3. Meanwhile, a comparative study of penta- to octasaccharides from the ST3 CPS concluded that a hexasaccharide-TT glycoconjugate is the most promising [<xref rid="BST-49-2411C40" ref-type="bibr">40</xref>,<xref rid="BST-49-2411C41" ref-type="bibr">41</xref>]. Nifantiev conducted the first study on the activation of the innate immune system in response to the semisynthetic glycoconjugate and selected a hexasaccharide of CPS ST14 conjugated to BSA as a vaccine candidate [<xref rid="BST-49-2411C42" ref-type="bibr">42</xref>].</p><p>Recent studies concerning the <italic toggle="yes">S. pneumoniae</italic> synthetic carbohydrate-based vaccine candidates involved chemical strategies to access the repeating unit of CPS ST19A [<xref rid="BST-49-2411C43" ref-type="bibr">43</xref>]. A chimeric antigen containing both repeating units of the ST19A and ST19F CPSs conferred substantial immunogenicity in rabbits. Antibodies produced in response to the semisynthetic chimeric glycoconjugate antigen neutralized ST19A and ST19F bacteria, while the conjugates containing other glycan epitopes failed (<xref rid="BST-49-2411F5" ref-type="fig">Figure 5</xref>) [<xref rid="BST-49-2411C44" ref-type="bibr">44</xref>]. A glycoconjugate ST14 pneumococcal vaccine with unique carrier-pneumococcal surface adhesin A (PsaA) [<xref rid="BST-49-2411C45" ref-type="bibr">45</xref>] investigated the role of the conjugation site in determining the immunogenicity of the glycoconjugate [<xref rid="BST-49-2411C46" ref-type="bibr">46</xref>]. Connecting the repeating unit of ST14 to an aliphatic spacer to simplify syntheses based on glycosidic linkages between repeating units of the ST14 CP yielded a neo-glycoconjugate with CRM<sub>197</sub> as a promising alternative with the advantage of a more straightforward synthesis [<xref rid="BST-49-2411C47" ref-type="bibr">47</xref>].</p><fig position="float" id="BST-49-2411F5" orientation="portrait"><label>Figure&#160;5.</label><caption><title>Synthetic carbohydrate antigens from Streptococcus. pneumoniae.</title><p>Chimeric antigen bearing both ST19F and ST19A [<xref rid="BST-49-2411C44" ref-type="bibr">44</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BST-49-2411-g0005.jpg"/></fig><p>To improve glycoconjugate vaccines in general, the relatively short linear ST3 and branched ST14 carbohydrate epitopes were attached to a virus-like particle (VLP) as a carrier to initiate both B and T cell-dependent immune responses, enabling loading of &#8764;20&#8211;200 antigens per VLP for both ST3 and ST14. The formulation was completed with a powerful adjuvant&#8212;an agonist glycolipid of NKT cells. This proof-of-concept glycoconjugate elicited serotype-specific, protective, and long-lasting IgG antibodies of nanomolar affinity in mice, proving the improved qualities of the new model [<xref rid="BST-49-2411C48" ref-type="bibr">48</xref>].</p></sec><sec id="s4b"><title>Streptococcus Groups A and B</title><p>The majority of Group A <italic toggle="yes">Streptococcus</italic> (GAS) infections cause relatively mild illnesses but can develop into the sometimes lethal streptococcal toxic shock syndrome. In total, due to diseases caused by GAS, over half a million people die globally each year. Since GAS is sensitive to commonly used antibiotics, constantly rising antibiotic resistance is of increasing concern regarding GAS infections and prophylaxis; thus, an effective vaccine remains a priority [<xref rid="BST-49-2411C49" ref-type="bibr">49</xref>].</p><p>A bivalent CPS&#8211;ScpA193 vaccine conjugate composed of synthetic oligosaccharides from the repeating unit of the major and the conserved cell wall polysaccharide from GAS STs conjugated to ScpA193, a novel streptococcal C5a peptidase (ScpA) mutant as the protein carrier. ScpA was identified as a potential target antigen for the development of an anti-GAS vaccine due to its high immunogenicity. Novel glycoconjugates with the ScpA193 protein elicited a strong carbohydrate&#8211;antigen-specific antibody response in mice. Moreover, the ScpA193 conjugates induced a robust anti-ScpA antibody response, proving the bivalency of the CPS&#8211;ScpA193 conjugate against GAS (<xref rid="BST-49-2411F6" ref-type="fig">Figure 6B</xref>) [<xref rid="BST-49-2411C50" ref-type="bibr">50</xref>]. Immunological studies in mice revealed that the nonasaccharide&#8211;ScpA193 glycoconjugate is a promising GAS vaccine candidate [<xref rid="BST-49-2411C51" ref-type="bibr">51</xref>]. Recent advances in the design of synthetic GAS glycoconjugate vaccines involve gold nanoparticles as a nano-vaccine platform. The carbohydrate structure in the proposed nano-vaccine were oligorhamnoside fragments, alternative antigens for anti-GAS vaccine, common to the cell wall of all GAS strains [<xref rid="BST-49-2411C52" ref-type="bibr">52</xref>].</p><fig position="float" id="BST-49-2411F6" orientation="portrait"><label>Figure&#160;6.</label><caption><title>Glycotope and a semisynthetic vaccine conjugate from capsular polysaccharides of Group A and B Streptococcus.</title><p>(<bold>A</bold>) &#8216;Diluted' hexasaccharide containing only the key residues necessary to elicit an immune response to Group B <italic toggle="yes">Streptococcus</italic> type III [<xref rid="BST-49-2411C54" ref-type="bibr">54&#8211;56</xref>]. (<bold>B</bold>) Group A CPS tethered to the ScpA193 protein conferring bivalent immunity [<xref rid="BST-49-2411C50" ref-type="bibr">50</xref>,<xref rid="BST-49-2411C51" ref-type="bibr">51</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BST-49-2411-g0006.jpg"/></fig><p>Group B <italic toggle="yes">Streptococci</italic> (GBS) are the leading cause of bacterial sepsis and meningitis in neonates and a significant source of neonatal morbidity globally. The vaccination of mothers in the third trimester against GBS is a promising alternative to antibiotics delivered intrapartum [<xref rid="BST-49-2411C57" ref-type="bibr">57</xref>]. Attempts toward a usable semisynthetic vaccine, described below, concern six out of nine GBS STs.</p><p>Since 2016, several synthetic methods for the oligosaccharide repeating units of GBS CPS were published: [<xref rid="BST-49-2411C1" ref-type="bibr">1</xref>] a dimer of the branched polysaccharide from ST Ia [<xref rid="BST-49-2411C53" ref-type="bibr">53</xref>]; (2) regioselective routes to building blocks that accessed the ST Ia and Ib repeating units [<xref rid="BST-49-2411C58" ref-type="bibr">58</xref>]; (3) the synthesis of three different pentasaccharide frameshifts of ST III [<xref rid="BST-49-2411C54" ref-type="bibr">54</xref>] that were later investigated as a decasaccharide fragment composed of two repeating units to reveal the portion necessary for antibody recognition [<xref rid="BST-49-2411C56" ref-type="bibr">56</xref>]; (4) a branched heptasaccharide of the repeating unit of ST II [<xref rid="BST-49-2411C59" ref-type="bibr">59</xref>]; (5) ST V [<xref rid="BST-49-2411C60" ref-type="bibr">60</xref>]; and (6) a hexasaccharide repeating unit with the dimer of this repeating unit from ST VII [<xref rid="BST-49-2411C61" ref-type="bibr">61</xref>]. A dimer of the branched pentasaccharide repeating unit from ST Ia and its corresponding monomer conjugated to CRM<sub>197</sub> resulted in robust antibody response in mice [<xref rid="BST-49-2411C53" ref-type="bibr">53</xref>]. A dimer fragment composed of two pentasaccharide repeating units from ST III could be shortened to a hexasaccharide representing the minimal antigenic portion. After subsequent conjugation to the CRM<sub>197</sub> carrier protein, the semisynthetic vaccine candidate elicited immune responses at similar levels to the native polysaccharide conjugate (<xref rid="BST-49-2411F6" ref-type="fig">Figure 6A</xref>) [<xref rid="BST-49-2411C54" ref-type="bibr">54&#8211;56</xref>].</p></sec><sec id="s4c"><title>
Neisseria meningitidis
</title><p><italic toggle="yes">Neisseria meningitidis</italic> (<italic toggle="yes">N. meningitis</italic>) is a Gram-negative bacterium causing bacterial meningitis and sepsis. Among the twelve different serogroups, the six most common serogroups, A, B, C, W, X, and Y, cause most of the epidemics globally. Meningococcal infections can be prevented with vaccines [<xref rid="BST-49-2411C62" ref-type="bibr">62</xref>]. Similar to the vaccines preventing <italic toggle="yes">S. pneumoniae</italic> infections, there are multiple vaccines available against <italic toggle="yes">N. meningitidis</italic> based on isolated CPSs, for example, polysaccharide vaccine Menomune-A/C/Y/W-135 (Sanofi Pasteur Inc., PA, U.S.A.)<xref rid="FN0002" ref-type="fn"><sup>2</sup></xref>
<fn id="FN0002"><p><sup>2</sup><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/media/83562/download" ext-link-type="uri">https://www.fda.gov/media/83562/download</ext-link></p></fn> and MenQuadfi (Sanofi Pasteuer Inc., PA, U.S.A.)<xref rid="FN0003" ref-type="fn"><sup>3</sup></xref>
<fn id="FN0003"><p><sup>3</sup><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/media/137306/download" ext-link-type="uri">https://www.fda.gov/media/137306/download</ext-link></p></fn>, a newly US-approved conjugate vaccine. Nevertheless, to date, there is no licensed vaccine against serogroup X, and scientific efforts aim to improve licensed vaccines with semisynthetic glycoconjugates and provide vaccine solutions against the increasing rates of serogroup X are necessitated [<xref rid="BST-49-2411C62" ref-type="bibr">62</xref>].</p><p>A rapid and cost-effective chemoenzymatic synthesis of oligosaccharides from <italic toggle="yes">N. meningitidis</italic> serogroup X produced glycans that elicited functional antibodies in mice (<xref rid="BST-49-2411F7" ref-type="fig">Figure 7</xref> bottom) [<xref rid="BST-49-2411C63" ref-type="bibr">63</xref>]. A vaccine candidate involving glycomimetics that stabilizes the natural CPS of <italic toggle="yes">N. meningitis</italic> serogroup A after conjugation to CRM<sub>197</sub> elicited in mice high levels of protective antibodies with bactericidal activity [<xref rid="BST-49-2411C64" ref-type="bibr">64</xref>], which advanced previous work that had used the synthetic tetrasaccharide conjugate of TT [<xref rid="BST-49-2411C65" ref-type="bibr">65</xref>]. The structural epitopes of <italic toggle="yes">N. meningitidis</italic> serogroup A revealed the importance of acetylation of the respective CPS [<xref rid="BST-49-2411C66" ref-type="bibr">66</xref>]. A semisynthetic vaccine composed of oligosaccharides from the <italic toggle="yes">N. meningitidis</italic> serogroup C conjugated to the TT proved antigenic in mice. The vaccine candidate elicited similar levels of IgG antibodies to those elicited by a commercial tetravalent vaccine (<xref rid="BST-49-2411F7" ref-type="fig">Figure 7</xref>, top) [<xref rid="BST-49-2411C67" ref-type="bibr">67</xref>].</p><fig position="float" id="BST-49-2411F7" orientation="portrait"><label>Figure&#160;7.</label><caption><title>The structure of a glycotope and a glycoconjugate vaccine candidate against Neisseria meningitidis.</title><p>Semisynthetic glycoconjugates of <italic toggle="yes">N. meningitidis</italic> serogroup X [<xref rid="BST-49-2411C63" ref-type="bibr">63</xref>] and C [<xref rid="BST-49-2411C67" ref-type="bibr">67</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BST-49-2411-g0007.jpg"/></fig><p>In addition to the many semisynthetic vaccine candidates targeting various <italic toggle="yes">N. meningitidis</italic> serogroups, the first fully synthetic vaccine candidate targeting <italic toggle="yes">N. meningitidis</italic> serogroup C is composed of oligosialic acids, an important CPS expressed by serogroup C <italic toggle="yes">N. meningitidis</italic> and the strong self-adjuvating immunostimulant MPLA glycolipid (<xref rid="BST-49-2411F8" ref-type="fig">Figure 8A</xref>). Immunological studies of this fully synthetic conjugate in mice revealed robust immune responses, proving that this vaccine candidate is worth further investigation [<xref rid="BST-49-2411C21" ref-type="bibr">21</xref>]; however, to date, no clinical studies have been further reported. A core lipotetrasaccharide Hep<sub>2</sub>Kdo<sub>2</sub>, a common motif in bacterial LPS, was selected as a vaccine candidate targeting various <italic toggle="yes">N. meningitidis</italic> strains and other pathogenic bacteria. The first synthesis of this tetrasaccharide, followed by its conjugation to the DT carrier protein, yielded glycoconjugates that resulted in antibodies capable of binding not only to <italic toggle="yes">N. meningitidis</italic> strains but also <italic toggle="yes">Pseudomonas aeruginosa</italic> and <italic toggle="yes">Escherichia coli</italic> (<xref rid="BST-49-2411F8" ref-type="fig">Figure 8B</xref>) [<xref rid="BST-49-2411C68" ref-type="bibr">68</xref>].</p><fig position="float" id="BST-49-2411F8" orientation="portrait"><label>Figure&#160;8.</label><caption><title>The structures of fully synthetic and multipotent vaccine candidates against Neisseria meningitidis.</title><p>(<bold>A</bold>) Fully synthetic vaccine target against <italic toggle="yes">N. meningitidis</italic> [<xref rid="BST-49-2411C21" ref-type="bibr">21</xref>]. (<bold>B</bold>) Semisynthetic multipotent vaccine candidate against <italic toggle="yes">N</italic>. <italic toggle="yes">meningitidis</italic> and other bacteria [<xref rid="BST-49-2411C68" ref-type="bibr">68</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BST-49-2411-g0008.jpg"/></fig></sec><sec id="s4d"><title>
Shigella flexneri
</title><p>Shigellosis, a common debilitating diarrheal disease, especially among children under five in developing countries, is caused by Gram-negative bacteria of the genus <italic toggle="yes">Shigella</italic>. The most prevalent strain worldwide is <italic toggle="yes">Shigella flexneri</italic> (<italic toggle="yes">S. flexneri</italic>) 2a [<xref rid="BST-49-2411C69" ref-type="bibr">69</xref>]. There are currently no licensed vaccines against <italic toggle="yes">Shigella</italic>.</p><p>A bioconjugation protocol was tested on a vaccine candidate for <italic toggle="yes">S. flexneri 2a</italic> infections, and it highlights the importance of the hapten:carrier ratio for immunogenicity. The semisynthetic glycoconjugate with TT was immunogenic in mice [<xref rid="BST-49-2411C70" ref-type="bibr">70</xref>]. Another semisynthetic vaccine candidate, SF2a&#8211;TT15, comprised of the oligosaccharide from the repeating unit of the O antigen from <italic toggle="yes">S. flexneri</italic> 2a conjugated to the TT carrier protein has successfully been tested in a phase I clinical trial [<xref rid="BST-49-2411C71" ref-type="bibr">71</xref>] and a phase 2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04078022">NCT04078022</ext-link>) trial is currently recruiting [<xref rid="BST-49-2411C72" ref-type="bibr">72</xref>].</p></sec><sec id="s4e"><title>
Salmonella enterica
</title><p><italic toggle="yes">Salmonella enterica</italic> serovar Typhi (<italic toggle="yes">S</italic>. Typhi), a pathogenic agent causing typhoid fever, leads to millions of infections annually worldwide. The currently licensed polysaccharide vaccine, Typhim Vi (Sanofi Pasteur SA, France), contains cell surface Vi polysaccharide from <italic toggle="yes">S.</italic> Typhi isolated from wild-type bacteria [<xref rid="BST-49-2411C73" ref-type="bibr">73</xref>]. A vaccine candidate comprised of the synthetic Vi antigen (GelSite-OAc&#8482;) based on <italic toggle="yes">O</italic>-acetylation of a novel high-molecular-weight polygalacturonic acid (GelSite) from <italic toggle="yes">Aloe vera</italic> was proposed since the high-molecular-weight polygalacturonic acid shares the same backbone. Interestingly, the pure polysaccharide elicited a boosting effect and an increase in specific IgG levels, indicating a T cell-dependent response even in the absence of a carrier protein. Immunological evaluation in mice showed induction of a strong antigen-specific and protective antibody response that was comparable to or higher than the antibody response induced by the licensed Vi vaccine, proving that this polysaccharide could be effective against <italic toggle="yes">S.</italic> Typhi [<xref rid="BST-49-2411C74" ref-type="bibr">74</xref>].</p><p>The synthetic approach is promising but complicated due to the presence of repeating &#945;1,4 (<italic toggle="yes">cis</italic>) linkages found in the Vi CPS of <italic toggle="yes">S.</italic> Typhi (<xref rid="BST-49-2411F9" ref-type="fig">Figure 9</xref>). After the importance of the acetyl groups in providing antigenicity [<xref rid="BST-49-2411C75" ref-type="bibr">75</xref>] was realized, Vi pseudooligosaccharides mimicking the Vi polysaccharide from <italic toggle="yes">S.</italic> Typhi were synthesized, while simplifying the synthesis of the full-length oligosaccharides [<xref rid="BST-49-2411C76" ref-type="bibr">76</xref>]. A series of synthetic Vi oligosaccharides revealed the hexasaccharide as the possible minimum epitope of the Vi antigen from <italic toggle="yes">S</italic>. Typhi [<xref rid="BST-49-2411C77" ref-type="bibr">77</xref>].</p><fig position="float" id="BST-49-2411F9" orientation="portrait"><label>Figure&#160;9.</label><caption><title>Glycotope structure from Salmonella.</title><p>The Vi CPS of <italic toggle="yes">S.</italic> Typhi bearing synthetically daunting &#945;1&#8211;4 (<italic toggle="yes">cis</italic>) glycosidic linkages [<xref rid="BST-49-2411C75" ref-type="bibr">75</xref>,<xref rid="BST-49-2411C76" ref-type="bibr">76</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BST-49-2411-g0009.jpg"/></fig><p><italic toggle="yes">Salmonella enterica</italic> serovar Enteriditis (<italic toggle="yes">S.</italic> Enteriditis) is one of the most prevalent strains of non-typhoidal <italic toggle="yes">Salmonella</italic> and the causative agent of serious and fatal systemic infections. There are currently no licensed vaccines preventing non-typhoidal <italic toggle="yes">Salmonella</italic> infections. The first synthetic carbohydrate-based anti-<italic toggle="yes">S. Enteriditis</italic> vaccine candidate is based on conjugation of the synthetic tetrasaccharide repeating unit of the <italic toggle="yes">S. Enteriditis</italic> O-polysaccharide of LPS to the bacteriophage Q&#946; as the carrier. The bacteriophage Q&#946; was shown to be an effective carrier in anticancer and anti-inflammation vaccines. Nevertheless, this study utilizes the bacteriophage Q&#946; in a carbohydrate-based antibacterial vaccine for the first time. The tetrasaccharide &#8212; Q&#946; conjugates elicited a potent IgG antibody response in mice and rabbits (<xref rid="BST-49-2411F10" ref-type="fig">Figure 10</xref>) [<xref rid="BST-49-2411C78" ref-type="bibr">78</xref>]. Later, the same concept of a vaccine candidate was tested with synthetic oligosaccharides from <italic toggle="yes">Salmonella enterica</italic> serovar <italic toggle="yes">Paratyphi A</italic> exhibiting potent IgG antibody responses in animals [<xref rid="BST-49-2411C79" ref-type="bibr">79</xref>].</p><fig position="float" id="BST-49-2411F10" orientation="portrait"><label>Figure&#160;10.</label><caption><title>The structure of a protective Q&#946;-glycoconjugate against Salmonella Enteriditis.</title><p><italic toggle="yes">S. Enteriditis</italic> vaccine candidate employing the Q&#946; bacteriophage [<xref rid="BST-49-2411C78" ref-type="bibr">78</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BST-49-2411-g0010.jpg"/></fig></sec><sec id="s4f"><title>
Vibrio cholerae
</title><p><italic toggle="yes">Vibrio cholerae</italic> (<italic toggle="yes">V. cholerae)</italic> is a pathogenic agent causing cholera, a severe diarrheal disease that can be fatal if left untreated. Synthetic LPS structures from <italic toggle="yes">V. cholerae</italic> O1, STs Ogawa, and Inaba have been prepared, but work on <italic toggle="yes">V. cholerae</italic> O139 has been hindered by the challenging synthesis of the critical hexasaccharide (<xref rid="BST-49-2411F11" ref-type="fig">Figure 11</xref>) [<xref rid="BST-49-2411C80" ref-type="bibr">80</xref>]. From the four oral-inactivated or non-live cholera vaccines available, only two contain the <italic toggle="yes">V. cholerae</italic> serogroup O139: (1) ShanChol (Shantha Biotechnics Limited, India) [<xref rid="BST-49-2411C81" ref-type="bibr">81</xref>] and (2) Euvichol (Eubiologics, South Korea) [<xref rid="BST-49-2411C82" ref-type="bibr">82</xref>]; however, these cholera vaccines are World Health Organization prequalified and not available in the United States [<xref rid="BST-49-2411C83" ref-type="bibr">83</xref>].</p><fig position="float" id="BST-49-2411F11" orientation="portrait"><label>Figure&#160;11.</label><caption><title>Synthetically available antigen of <italic toggle="yes">V. cholerae</italic> [<xref rid="BST-49-2411C80" ref-type="bibr">80</xref>].</title><p>O-antigen</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BST-49-2411-g0011.jpg"/></fig><p>The first chemical synthesis of the complete protective ready-for-conjugation antigen of <italic toggle="yes">V. cholerae</italic> O139 [<xref rid="BST-49-2411C80" ref-type="bibr">80</xref>] was improved from a small-scale chemical synthesis into a less demanding experimental method. A linker-equipped synthesis of the O-specific polysaccharide of <italic toggle="yes">V. cholerae</italic> O139 allowed for conjugation to a carrier protein, BSA (<xref rid="BST-49-2411F11" ref-type="fig">Figure 11</xref>) [<xref rid="BST-49-2411C84" ref-type="bibr">84</xref>]. Glycoclusters displaying synthetic oligosaccharides of the O-specific polysaccharide of <italic toggle="yes">V. cholerae</italic> O1 ST Inaba were conjugated to BSA. The immunoreactivity of the glycoclusters was studied using plasma of patients recovering from cholera. The synthetic glycoclusters showed similar immunoreactivity compared with conventional oligosaccharide conjugates from wild-type bacteria [<xref rid="BST-49-2411C85" ref-type="bibr">85</xref>].</p></sec><sec id="s4g"><title><italic toggle="yes">Burkholderia pseudomallei</italic> and <italic toggle="yes">Burkholderia mallei</italic></title><p><italic toggle="yes">Burkholderia pseudomallei</italic> (<italic toggle="yes">B. pseudomallei)</italic> is a bacterium causing melioidosis leading to death in up to 50% of patients. <italic toggle="yes">Burkholderia mallei</italic> (<italic toggle="yes">B. mallei)</italic> is a bacterium that causes glanders in solipeds; however, it may be transmitted into humans leading to fatal infections if left untreated. Currently, there are no clinically approved prophylactic vaccines on the market for either of these pathogens [<xref rid="BST-49-2411C86" ref-type="bibr">86</xref>].</p><p>A synthetic hexasaccharide fragment from the CPS of <italic toggle="yes">B. pseudomallei</italic> was coupled to the nontoxic H<sub>C</sub> domain of TT, showing immunologically relevant and protective properties in mice [<xref rid="BST-49-2411C87" ref-type="bibr">87</xref>]. Seven minimal epitopes from <italic toggle="yes">B. pseudomallei</italic> and <italic toggle="yes">B. mallei</italic> lipopolysaccharide O-antigens were synthesized. Immunization of mice using the two terminal disaccharides that comprise the lipopolysaccharide O-antigens&#8217; epitopes from <italic toggle="yes">B. pseudomallei</italic> and <italic toggle="yes">B. mallei</italic> conjugated to the CRM<sub>197</sub> carrier protein showed high-titer IgG responses against one of the disaccharides [<xref rid="BST-49-2411C88" ref-type="bibr">88</xref>]. Synthetic fragments of the common and major capsular polysaccharide, type I O-PS from <italic toggle="yes">B. pseudomallei</italic> and <italic toggle="yes">B. mallei</italic> conjugated to CRM<sub>197</sub> carrier protein elicited high titers of IgG antibodies and a robust T-cell-dependent immune response in mice [<xref rid="BST-49-2411C89" ref-type="bibr">89</xref>] (<xref rid="BST-49-2411F12" ref-type="fig">Figure 12A</xref>). Tetrasaccharide structures of the native O-polysaccharide of LPS from <italic toggle="yes">Burkoholderia</italic> sp. were found to be strongly reactive in sera from meliodosis patients (<xref rid="BST-49-2411F12" ref-type="fig">Figure 12B</xref>) [<xref rid="BST-49-2411C90" ref-type="bibr">90</xref>].</p><fig position="float" id="BST-49-2411F12" orientation="portrait"><label>Figure&#160;12.</label><caption><title>Synthetic capsular polysaccharides from Burkholderia.</title><p>(<bold>A</bold>) Homologated polymannosides confer T-cell-dependent immunity against <italic toggle="yes">B. pseudomallei</italic> and <italic toggle="yes">B. mallei</italic> [<xref rid="BST-49-2411C89" ref-type="bibr">89</xref>]. (<bold>B</bold>) Synthetic lipopolysaccharide O-polysaccharide of <italic toggle="yes">Burkoholderia</italic> [<xref rid="BST-49-2411C90" ref-type="bibr">90</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BST-49-2411-g0012.jpg"/></fig></sec></sec><sec id="s5"><title>Conclusions and outlook</title><p>Due to their proven success, antibacterial semisynthetic and fully synthetic vaccines will remain an important area of research. Since the first marketed carbohydrate-based vaccine in 1947 and the first semisynthetic carbohydrate-based vaccine commercialized in 2004, the field has advanced steadily. Just the last five years covered in this mini-review have seen impressive developments.</p><p>Recent advances have offered vaccine candidates composed of adjuvants on a sole (macro)molecule triggering T and B cells concurrently, regardless of a carrier protein. Alongside novel synthetic tools, as MPLA incorporated liposomal, carbohydrate-based particles, and additional non-protein T cell-activating carriers, the field of antibacterial carbohydrate vaccines holds great promise.</p><p>To produce a commercial synthetic vaccine, limiting the number of requisite synthetic steps while still achieving the desired, specific immune response is of fundamental importance. Synthetic chemistry is cumbersome and time-consuming, often providing the greatest bottleneck in pharmaceuticals. Despite the inherent possibility to expedite production and enhance the purity of the overall vaccine formulation by depending on synthetic chemistry, a minimalistic strategy &#8212; hopefully facilitated through improvements in automated glycan assembly &#8212; is paramount to availing the first licensed fully synthetic vaccine. At this time, targeting <italic toggle="yes">S. pneumoniae</italic> may hold the most promise toward achieving a synthetic vaccine, but many infections from other bacteria, such as <italic toggle="yes">N. meningitidis</italic>, could soon be prevented.</p><p>The COVID-19 pandemic highlights the urgent need for efficient vaccines, and the increased interest in vaccines of all varieties among the general population does offer excitement. We note that much like with the SARS-CoV-2 vaccines, providing availability to remote areas while maintaining affordability remains a challenge.</p></sec><sec sec-type="perspectives"><title>Perspectives</title><list list-type="bullet"><list-item><p><italic toggle="yes">Importance to the field:</italic> Although proven highly effective against human pathogenic bacteria for more than three decades, purified capsular polysaccharides for glycoconjugate vaccine production still pose many challenges. Semi- and fully synthetic glycoconjugate vaccines are steadily emerging as elegant solutions that bypass the need for native carbohydrates while providing highly effective, long-lasting immune protection.</p></list-item><list-item><p><italic toggle="yes">Summary of current thinking:</italic> Although different exceptions were demonstrated, the ability to induce an adequate, long-lasting T cell-dependent immune protection against bacterial capsular polysaccharides is likely a combination of potent adjuvants, immunogenic carrier, and properly presented carbohydrate antigens by the MHC-II complex.</p></list-item><list-item><p><italic toggle="yes">Future directions:</italic> The greatest bottleneck in the design of semi- and fully synthetic vaccines may always remain the synthesis itself. Facilitating access to the active components of the vaccines in high purity at scale is an ongoing, longstanding interest in the field of vaccine design. Thus far, automated solid-phase methods have shown the most promise, with automated glycan assembly having an appreciable lead in this regard. Synthetic methodological advancements that are amenable to automated glycan assembly are certainly the way forward.</p></list-item></list></sec></body><back><ack><title>Acknowledgements</title><p>The authors would like to thank Dr. Maria Br&#228;utigam for constructive criticism of the manuscript and helpful discussion.</p></ack><sec sec-type="COI-statement" id="s6"><title>Competing Interests</title><p>The authors declare that there are no competing interests associated with the manuscript.</p></sec><sec sec-type="funding" id="s7"><title>Funding</title><p>We gratefully acknowledge generous financial support from the Max Planck Society to A.M.D, P.H.S and O.M, and the Deutsche Forschungsgemeinschaft (No. SFB-1340) to M.E.Z.</p></sec><sec sec-type="open-access" id="s8"><title>Open Access Statement</title><p>Open access for this article was enabled by the participation of Max Planck Digital Library in an all-inclusive Read &amp; Publish pilot with Portland Press and the Biochemical Society under a transformative agreement with Max Planck Digital Library.</p></sec><sec sec-type="author-contrib" id="s9"><title>Author Contributions</title><p>M.E.Z., A.M.D., and O.M. designed and wrote the review. P.H.S. revised the manuscript.</p></sec><glossary><title>Abbreviations</title><def-list list-content="abbreviations"><def-item><term id="uid1">BSA</term><def><p>bovine serum albumin</p></def></def-item><def-item><term id="uid01">CPS</term><def><p>capsular polysaccharide</p></def></def-item><def-item><term id="uid2">D-AAT</term><def><p>2-acetamido-4-amino-2,4,6-trideoxy-D-galactose</p></def></def-item><def-item><term id="uid3">DT</term><def><p>diphtheria toxoid</p></def></def-item><def-item><term id="uid4">GAS</term><def><p>Group A <italic toggle="yes">Streptococcus</italic></p></def></def-item><def-item><term id="uid5">GBS</term><def><p>Group B <italic toggle="yes">Streptococci</italic></p></def></def-item><def-item><term id="uid6">MHC</term><def><p>major histocompatibility complex</p></def></def-item><def-item><term id="uid7">MPLA</term><def><p>monophosphoryl lipid A</p></def></def-item><def-item><term id="uid8">OMPC</term><def><p>outer membrane protein complex</p></def></def-item><def-item><term id="uid9">ST</term><def><p>serotypes</p></def></def-item><def-item><term id="uid10">TT</term><def><p>tetanus toxoid</p></def></def-item><def-item><term id="uid11">VLP</term><def><p>virus-like particle</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="BST-49-2411C1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Astronomo</surname>, <given-names>R.D.</given-names></string-name> and <string-name name-style="western"><surname>Burton</surname>, <given-names>D.R.</given-names></string-name></person-group> (<year>2010</year>) <article-title>Carbohydrate vaccines: developing sweet solutions to sticky situations?</article-title><source>Nat. Rev. Drug. Discov.</source><volume>9</volume>, <fpage>308</fpage>&#8211;<lpage>324</lpage><pub-id pub-id-type="doi">10.1038/nrd3012</pub-id><pub-id pub-id-type="pmid">20357803</pub-id><pub-id pub-id-type="pmcid">PMC3878310</pub-id></mixed-citation></ref><ref id="BST-49-2411C2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Verez-Bencomo</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western"><surname>Fernandez-Santana</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western"><surname>Hardy</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Toledo</surname>, <given-names>M.E.</given-names></string-name>, <string-name name-style="western"><surname>Rodriguez</surname>, <given-names>M.C.</given-names></string-name>, <string-name name-style="western"><surname>Heynngnezz</surname>, <given-names>L.</given-names></string-name><etal>et al.</etal></person-group> (<year>2004</year>) <article-title>A synthetic conjugate polysaccharide vaccine against <italic toggle="yes">Haemophilus influenzae</italic> type b</article-title>. <source>Science</source><volume>305</volume>, <fpage>522</fpage>&#8211;<lpage>525</lpage><pub-id pub-id-type="doi">10.1126/science.1095209</pub-id><pub-id pub-id-type="pmid">15273395</pub-id></mixed-citation></ref><ref id="BST-49-2411C3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Seeberger</surname>, <given-names>P.H.</given-names></string-name></person-group> (<year>2021</year>) <article-title>Discovery of semi- and fully-synthetic carbohydrate vaccines against bacterial infections using a medicinal chemistry approach</article-title>. <source>Chem. Rev.</source><volume>121</volume>, <fpage>3598</fpage>&#8211;<lpage>3626</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.0c01210</pub-id><pub-id pub-id-type="pmid">33794090</pub-id><pub-id pub-id-type="pmcid">PMC8154330</pub-id></mixed-citation></ref><ref id="BST-49-2411C4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gold</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Lepow</surname>, <given-names>M.L.</given-names></string-name>, <string-name name-style="western"><surname>Goldschneider</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western"><surname>Draper</surname>, <given-names>T.L.</given-names></string-name> and <string-name name-style="western"><surname>Gotschlich</surname>, <given-names>E.C.</given-names></string-name></person-group> (<year>1975</year>) <article-title>Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants</article-title>. <source>J. Clin. Invest.</source><volume>56</volume>, <fpage>1536</fpage>&#8211;<lpage>1547</lpage><pub-id pub-id-type="doi">10.1172/JCI108235</pub-id><pub-id pub-id-type="pmid">1202084</pub-id><pub-id pub-id-type="pmcid">PMC333132</pub-id></mixed-citation></ref><ref id="BST-49-2411C5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Peltola</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Kayhty</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Sivonen</surname>, <given-names>A.</given-names></string-name> and <string-name name-style="western"><surname>Makela</surname>, <given-names>H.</given-names></string-name></person-group> (<year>1977</year>) <article-title>Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland</article-title>. <source>Pediatrics</source><volume>60</volume>, <fpage>730</fpage>&#8211;<lpage>737</lpage> PMID:<pub-id pub-id-type="pmid">335348</pub-id></mixed-citation></ref><ref id="BST-49-2411C6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kayhty</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Karanko</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western"><surname>Peltola</surname>, <given-names>H.</given-names></string-name> and <string-name name-style="western"><surname>Makela</surname>, <given-names>P.H.</given-names></string-name></person-group> (<year>1984</year>) <article-title>Serum antibodies after vaccination with <italic toggle="yes">Haemophilus influenzae</italic> type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory</article-title>. <source>Pediatrics</source><volume>74</volume>, <fpage>857</fpage>&#8211;<lpage>865</lpage> PMID:<pub-id pub-id-type="pmid">6387614</pub-id></mixed-citation></ref><ref id="BST-49-2411C7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Avery</surname>, <given-names>O.T.</given-names></string-name> and <string-name name-style="western"><surname>Goebel</surname>, <given-names>W.F.</given-names></string-name></person-group> (<year>1929</year>) <article-title>Chemo-immunological studies on conjugated carbohydrate-proteins&#8239;: II. Immunological specificity of synthetic sugar-protein antigens</article-title>. <source>J. Exp. Med.</source><volume>50</volume>, <fpage>533</fpage>&#8211;<lpage>550</lpage><pub-id pub-id-type="doi">10.1084/jem.50.4.533</pub-id><pub-id pub-id-type="pmid">19869645</pub-id><pub-id pub-id-type="pmcid">PMC2131643</pub-id></mixed-citation></ref><ref id="BST-49-2411C8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Avci</surname>, <given-names>F.Y.</given-names></string-name>, <string-name name-style="western"><surname>Li</surname>, <given-names>X.</given-names></string-name>, <string-name name-style="western"><surname>Tsuji</surname>, <given-names>M.</given-names></string-name> and <string-name name-style="western"><surname>Kasper</surname>, <given-names>D.L.</given-names></string-name></person-group> (<year>2011</year>) <article-title>A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design</article-title>. <source>Nat. Med.</source><volume>17</volume>, <fpage>1602</fpage>&#8211;<lpage>1609</lpage><pub-id pub-id-type="doi">10.1038/nm.2535</pub-id><pub-id pub-id-type="pmid">22101769</pub-id><pub-id pub-id-type="pmcid">PMC3482454</pub-id></mixed-citation></ref><ref id="BST-49-2411C9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rappuoli</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>De Gregorio</surname>, <given-names>E.</given-names></string-name> and <string-name name-style="western"><surname>Costantino</surname>, <given-names>P.</given-names></string-name></person-group> (<year>2019</year>) <article-title>On the mechanisms of conjugate vaccines</article-title>. <source>Proc. Natl Acad. Sci. U.S.A.</source><volume>116</volume>, <fpage>14</fpage>&#8211;<lpage>16</lpage><pub-id pub-id-type="doi">10.1073/pnas.1819612116</pub-id><pub-id pub-id-type="pmid">30578318</pub-id><pub-id pub-id-type="pmcid">PMC6320500</pub-id></mixed-citation></ref><ref id="BST-49-2411C10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schneerson</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Barrera</surname>, <given-names>O.</given-names></string-name>, <string-name name-style="western"><surname>Sutton</surname>, <given-names>A.</given-names></string-name> and <string-name name-style="western"><surname>Robbins</surname>, <given-names>J.B.</given-names></string-name></person-group> (<year>1980</year>) <article-title>Preparation, characterization, and immunogenicity of <italic toggle="yes">Haemophilus influenzae</italic> type b polysaccharide-protein conjugates</article-title>. <source>J. Exp. Med.</source><volume>152</volume>, <fpage>361</fpage>&#8211;<lpage>376</lpage><pub-id pub-id-type="doi">10.1084/jem.152.2.361</pub-id><pub-id pub-id-type="pmid">6967514</pub-id><pub-id pub-id-type="pmcid">PMC2185954</pub-id></mixed-citation></ref><ref id="BST-49-2411C11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Micoli</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><surname>Adamo</surname>, <given-names>R.</given-names></string-name> and <string-name name-style="western"><surname>Costantino</surname>, <given-names>P.</given-names></string-name></person-group> (<year>2018</year>) <article-title>Protein carriers for glycoconjugate vaccines: history, selection criteria, characterization and new trends</article-title>. <source>Molecules</source><volume>23</volume>, <fpage>1451</fpage><pub-id pub-id-type="doi">10.3390/molecules23061451</pub-id><pub-id pub-id-type="pmcid">PMC6100388</pub-id><pub-id pub-id-type="pmid">29914046</pub-id></mixed-citation></ref><ref id="BST-49-2411C12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname>, <given-names>Q.</given-names></string-name> and <string-name name-style="western"><surname>Guo</surname>, <given-names>Z.</given-names></string-name></person-group> (<year>2018</year>) <article-title>Recent advances in toll like receptor-targeting glycoconjugate vaccines</article-title>. <source>Molecules</source><volume>23</volume>, <fpage>1583</fpage><pub-id pub-id-type="doi">10.3390/molecules23071583</pub-id><pub-id pub-id-type="pmcid">PMC6100623</pub-id><pub-id pub-id-type="pmid">29966261</pub-id></mixed-citation></ref><ref id="BST-49-2411C13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mettu</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname>, <given-names>C.-Y.</given-names></string-name> and <string-name name-style="western"><surname>Wu</surname>, <given-names>C.-Y.</given-names></string-name></person-group> (<year>2020</year>) <article-title>Synthetic carbohydrate-based vaccines: challenges and opportunities</article-title>. <source>J. Biomed. Sci.</source><volume>27</volume>, <fpage>9</fpage><pub-id pub-id-type="doi">10.1186/s12929-019-0591-0</pub-id><pub-id pub-id-type="pmid">31900143</pub-id><pub-id pub-id-type="pmcid">PMC6941340</pub-id></mixed-citation></ref><ref id="BST-49-2411C14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hutter</surname>, <given-names>J.</given-names></string-name> and <string-name name-style="western"><surname>Lepenies</surname>, <given-names>B.</given-names></string-name></person-group> (<year>2015</year>) <article-title>Carbohydrate-based vaccines: an overview</article-title>. <source>Methods Mol. Biol.</source><volume>1331</volume>, <fpage>1</fpage>&#8211;<lpage>10</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-2874-3_1</pub-id><pub-id pub-id-type="pmid">26169731</pub-id></mixed-citation></ref><ref id="BST-49-2411C15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Costantino</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Rappuoli</surname>, <given-names>R.</given-names></string-name> and <string-name name-style="western"><surname>Berti</surname>, <given-names>F.</given-names></string-name></person-group> (<year>2011</year>) <article-title>The design of semi-synthetic and synthetic glycoconjugate vaccines</article-title>. <source>Expert Opin. Drug Discov.</source><volume>6</volume>, <fpage>1045</fpage>&#8211;<lpage>1066</lpage><pub-id pub-id-type="doi">10.1517/17460441.2011.609554</pub-id><pub-id pub-id-type="pmid">22646863</pub-id></mixed-citation></ref><ref id="BST-49-2411C16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rappuoli</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Black</surname>, <given-names>S.</given-names></string-name> and <string-name name-style="western"><surname>Lambert</surname>, <given-names>P.H.</given-names></string-name></person-group> (<year>2011</year>) <article-title>Vaccine discovery and translation of new vaccine technology</article-title>. <source>Lancet (London, England)</source><volume>378</volume>, <fpage>360</fpage>&#8211;<lpage>368</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(11)60440-6</pub-id><pub-id pub-id-type="pmid">21664687</pub-id></mixed-citation></ref><ref id="BST-49-2411C17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Anish</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Schumann</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Pereira</surname>, <given-names>C.L.</given-names></string-name> and <string-name name-style="western"><surname>Seeberger</surname>, <given-names>P.H.</given-names></string-name></person-group> (<year>2014</year>) <article-title>Chemical biology approaches to designing defined carbohydrate vaccines</article-title>. <source>Chem. Biol.</source><volume>21</volume>, <fpage>38</fpage>&#8211;<lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2014.01.002</pub-id><pub-id pub-id-type="pmid">24439205</pub-id></mixed-citation></ref><ref id="BST-49-2411C18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Peri</surname>, <given-names>F.</given-names></string-name></person-group> (<year>2013</year>) <article-title>Clustered carbohydrates in synthetic vaccines</article-title>. <source>Chem. Soc. Rev.</source><volume>42</volume>, <fpage>4543</fpage>&#8211;<lpage>4556</lpage><pub-id pub-id-type="doi">10.1039/C2CS35422E</pub-id><pub-id pub-id-type="pmid">23250562</pub-id><pub-id pub-id-type="pmcid">PMC3654047</pub-id></mixed-citation></ref><ref id="BST-49-2411C19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lang</surname>, <given-names>S.</given-names></string-name> and <string-name name-style="western"><surname>Huang</surname>, <given-names>X.</given-names></string-name></person-group> (<year>2020</year>) <article-title>Carbohydrate conjugates in vaccine developments</article-title>. <source>Front. Chem.</source><volume>8</volume>, <fpage>284</fpage><pub-id pub-id-type="doi">10.3389/fchem.2020.00284</pub-id><pub-id pub-id-type="pmid">32351942</pub-id><pub-id pub-id-type="pmcid">PMC7174737</pub-id></mixed-citation></ref><ref id="BST-49-2411C20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pifferi</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Berthet</surname>, <given-names>N.</given-names></string-name> and <string-name name-style="western"><surname>Renaudet</surname>, <given-names>O.</given-names></string-name></person-group> (<year>2017</year>) <article-title>Cyclopeptide scaffolds in carbohydrate-based synthetic vaccines</article-title>. <source>Biomater. Sci.</source><volume>5</volume>, <fpage>953</fpage>&#8211;<lpage>965</lpage><pub-id pub-id-type="doi">10.1039/C7BM00072C</pub-id><pub-id pub-id-type="pmid">28275765</pub-id></mixed-citation></ref><ref id="BST-49-2411C21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liao</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname>, <given-names>Z.</given-names></string-name>, <string-name name-style="western"><surname>Suryawanshi</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Mondal</surname>, <given-names>M.A.</given-names></string-name> and <string-name name-style="western"><surname>Guo</surname>, <given-names>Z.</given-names></string-name></person-group> (<year>2016</year>) <article-title>Fully synthetic self-adjuvanting a-2,9-oligosialic acid based conjugate vaccines against group C meningitis</article-title>. <source>ACS Cent. Sci.</source><volume>2</volume>, <fpage>210</fpage>&#8211;<lpage>218</lpage><pub-id pub-id-type="doi">10.1021/acscentsci.5b00364</pub-id><pub-id pub-id-type="pmid">27163051</pub-id><pub-id pub-id-type="pmcid">PMC4850515</pub-id></mixed-citation></ref><ref id="BST-49-2411C22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname>, <given-names>G.-L.</given-names></string-name>, <string-name name-style="western"><surname>Seon</surname>, <given-names>S.-H.</given-names></string-name> and <string-name name-style="western"><surname>Rhee</surname>, <given-names>D.-K.</given-names></string-name></person-group> (<year>2017</year>) <article-title>Pneumonia and <italic toggle="yes">Streptococcus pneumoniae</italic> vaccine</article-title>. <source>Arch. Pharm. Res.</source><volume>40</volume>, <fpage>885</fpage>&#8211;<lpage>893</lpage><pub-id pub-id-type="doi">10.1007/s12272-017-0933-y</pub-id><pub-id pub-id-type="pmid">28735461</pub-id><pub-id pub-id-type="pmcid">PMC7090487</pub-id></mixed-citation></ref><ref id="BST-49-2411C23"><label>23</label><mixed-citation publication-type="std"><comment>GlaxoSmithKline. Synflorix, Pneumococcal polysaccharide conjugate vaccine. Summars of product characteristics. Eur Med Agency. 2009</comment></mixed-citation></ref><ref id="BST-49-2411C24"><label>24</label><mixed-citation publication-type="std"><comment>Wyeth Pharmaceuticals, Inc. Prevnar 13 [package insert]. U.S. Food and Drug Administration website</comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/media/107657/download" ext-link-type="uri">https://www.fda.gov/media/107657/download</ext-link>. <comment>Revised 2019 November 12. Accessed 2020 April 25</comment></mixed-citation></ref><ref id="BST-49-2411C25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Clarke</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Bashorun</surname>, <given-names>A.O.</given-names></string-name>, <string-name name-style="western"><surname>Okoye</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Umesi</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Badjie Hydara</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Adigweme</surname>, <given-names>I.</given-names></string-name><etal>et al.</etal></person-group> (<year>2020</year>) <article-title>Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia-Results of a phase 1/2 randomized, double-blinded, controlled trial</article-title>. <source>Vaccine</source><volume>38</volume>, <fpage>399</fpage>&#8211;<lpage>410</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.08.072</pub-id><pub-id pub-id-type="pmid">31843266</pub-id></mixed-citation></ref><ref id="BST-49-2411C26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Emmadi</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Lykke</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Reppe</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Parameswarappa S</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Lisboa</surname>, <given-names>M.P.</given-names></string-name><etal>et al.</etal></person-group> (<year>2017</year>) <article-title>A <italic toggle="yes">Streptococcus pneumoniae</italic> type 2 oligosaccharide glycoconjugate elicits opsonic antibodies and is protective in an animal model of invasive pneumococcal disease</article-title>. <source>J. Am. Chem. Soc.</source><volume>139</volume>, <fpage>14783</fpage>&#8211;<lpage>14791</lpage><pub-id pub-id-type="doi">10.1021/jacs.7b07836</pub-id><pub-id pub-id-type="pmid">28945368</pub-id></mixed-citation></ref><ref id="BST-49-2411C27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Parameswarappa</surname>, <given-names>S.G.</given-names></string-name>, <string-name name-style="western"><surname>Reppe</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Geissner</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>M&#233;nov&#225;</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Govindan</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Calow</surname>, <given-names>A.D.J.</given-names></string-name><etal>et al.</etal></person-group> (<year>2016</year>) <article-title>A semi-synthetic oligosaccharide conjugate vaccine candidate confers protection against <italic toggle="yes">Streptococcus pneumoniae</italic> serotype 3 infection</article-title>. <source>Cell Chem. Biol.</source><volume>23</volume>, <fpage>1407</fpage>&#8211;<lpage>1416</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2016.09.016</pub-id><pub-id pub-id-type="pmid">27818299</pub-id><pub-id pub-id-type="pmcid">PMC5234679</pub-id></mixed-citation></ref><ref id="BST-49-2411C28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Geissner</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Pereira C</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Leddermann</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Anish</surname>, <given-names>C.</given-names></string-name> and <string-name name-style="western"><surname>Seeberger</surname>, <given-names>P.H.</given-names></string-name></person-group> (<year>2016</year>) <article-title>Deciphering antigenic determinants of <italic toggle="yes">Streptococcus pneumoniae</italic> serotype 4 capsular polysaccharide using synthetic oligosaccharides</article-title>. <source>ACS Chem. Biol.</source><volume>11</volume>, <fpage>335</fpage>&#8211;<lpage>344</lpage><pub-id pub-id-type="doi">10.1021/acschembio.5b00768</pub-id><pub-id pub-id-type="pmid">26674834</pub-id></mixed-citation></ref><ref id="BST-49-2411C29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>M&#233;nov&#225;</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Sella</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Sellrie</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Pereira</surname>, <given-names>C.L.</given-names></string-name> and <string-name name-style="western"><surname>Seeberger</surname>, <given-names>P.H.</given-names></string-name></person-group> (<year>2018</year>) <article-title>Identification of the minimal glycotope of <italic toggle="yes">Streptococcus pneumoniae</italic> 7F capsular polysaccharide using synthetic oligosaccharides</article-title>. <source>Chemistry</source><volume>24</volume>, <fpage>4181</fpage>&#8211;<lpage>4187</lpage><pub-id pub-id-type="doi">10.1002/chem.201705379</pub-id><pub-id pub-id-type="pmid">29333751</pub-id></mixed-citation></ref><ref id="BST-49-2411C30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schumann</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Hahm</surname>, <given-names>H.S.</given-names></string-name>, <string-name name-style="western"><surname>Parameswarappa</surname>, <given-names>S.G.</given-names></string-name>, <string-name name-style="western"><surname>Reppe</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Wahlbrink</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Govindan</surname>, <given-names>S.</given-names></string-name><etal>et al.</etal></person-group> (<year>2017</year>) <article-title>A semisynthetic <italic toggle="yes">Streptococcus pneumoniae</italic> serotype 8 glycoconjugate vaccine</article-title>. <source>Sci. Transl. Med.</source><volume>9</volume>, <fpage>eaaf5347</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aaf5347</pub-id><pub-id pub-id-type="pmid">28275152</pub-id><pub-id pub-id-type="pmcid">PMC5573155</pub-id></mixed-citation></ref><ref id="BST-49-2411C31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Parameswarappa</surname>, <given-names>S.G.</given-names></string-name>, <string-name name-style="western"><surname>Pereira</surname>, <given-names>C.L.</given-names></string-name> and <string-name name-style="western"><surname>Seeberger</surname>, <given-names>P.H.</given-names></string-name></person-group> (<year>2020</year>) <article-title>Synthesis of <italic toggle="yes">Streptococcus pneumoniae</italic> serotype 9V oligosaccharide antigens</article-title>. <source>Beilstein J. Org. Chem.</source><volume>16</volume>, <fpage>1693</fpage>&#8211;<lpage>1699</lpage><pub-id pub-id-type="doi">10.3762/bjoc.16.140</pub-id><pub-id pub-id-type="pmid">32733612</pub-id><pub-id pub-id-type="pmcid">PMC7372248</pub-id></mixed-citation></ref><ref id="BST-49-2411C32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Seeberger</surname>, <given-names>P.H.</given-names></string-name>, <string-name name-style="western"><surname>Pereira</surname>, <given-names>C.L.</given-names></string-name> and <string-name name-style="western"><surname>Govindan</surname>, <given-names>S.</given-names></string-name></person-group> (<year>2017</year>) <article-title>Total synthesis of a <italic toggle="yes">Streptococcus pneumoniae</italic> serotype 12F CPS repeating unit hexasaccharide</article-title>. <source>Beilstein J. Org. Chem.</source><volume>13</volume>, <fpage>164</fpage>&#8211;<lpage>173</lpage><pub-id pub-id-type="doi">10.3762/bjoc.13.19</pub-id><pub-id pub-id-type="pmid">28228857</pub-id><pub-id pub-id-type="pmcid">PMC5301915</pub-id></mixed-citation></ref><ref id="BST-49-2411C33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weishaupt</surname>, <given-names>M.W.</given-names></string-name>, <string-name name-style="western"><surname>Matthies</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Hurevich</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Pereira</surname>, <given-names>C.L.</given-names></string-name>, <string-name name-style="western"><surname>Hahm</surname>, <given-names>H.S.</given-names></string-name> and <string-name name-style="western"><surname>Seeberger</surname>, <given-names>P.H.</given-names></string-name></person-group> (<year>2016</year>) <article-title>Automated glycan assembly of a s. pneumoniae serotype 3 cps antigen</article-title>. <source>Beilstein J. Org. Chem.</source><volume>12</volume>, <fpage>1440</fpage>&#8211;<lpage>1446</lpage><pub-id pub-id-type="doi">10.3762/bjoc.12.139</pub-id><pub-id pub-id-type="pmid">27559395</pub-id><pub-id pub-id-type="pmcid">PMC4979738</pub-id></mixed-citation></ref><ref id="BST-49-2411C34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lisboa</surname>, <given-names>M.P.</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname>, <given-names>F.F.</given-names></string-name>, <string-name name-style="western"><surname>Reppe</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Geissner</surname>, <given-names>A.</given-names></string-name><etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Semisynthetic glycoconjugate vaccine candidate against <italic toggle="yes">Streptococcus pneumoniae</italic> serotype 5</article-title>. <source>Proc. Natl Acad. Sci. U.S.A.</source><volume>114</volume>, <fpage>11063</fpage>&#8211;<lpage>11068</lpage><pub-id pub-id-type="doi">10.1073/pnas.1706875114</pub-id><pub-id pub-id-type="pmid">28973947</pub-id><pub-id pub-id-type="pmcid">PMC5651752</pub-id></mixed-citation></ref><ref id="BST-49-2411C35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kaplonek</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Reppe</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Schumann</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Emmadi</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Lisboa</surname>, <given-names>M.P.</given-names></string-name><etal>et al.</etal></person-group> (<year>2018</year>) <article-title>Improving vaccines against <italic toggle="yes">Streptococcus pneumoniae</italic> using synthetic glycans</article-title>. <source>Proc. Natl Acad. Sci. U.S.A.</source><volume>115</volume>, <fpage>13353</fpage>&#8211;<lpage>13358</lpage><pub-id pub-id-type="doi">10.1073/pnas.1811862115</pub-id><pub-id pub-id-type="pmid">30530654</pub-id><pub-id pub-id-type="pmcid">PMC6310808</pub-id></mixed-citation></ref><ref id="BST-49-2411C36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schumann</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Reppe</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Kaplonek</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Wahlbrink</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Anish</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Witzenrath</surname>, <given-names>M.</given-names></string-name><etal>et al.</etal></person-group> (<year>2018</year>) <article-title>Development of an efficacious, semisynthetic glycoconjugate vaccine candidate against <italic toggle="yes">Streptococcus pneumoniae</italic> serotype 1</article-title>. <source>ACS Cent. Sci.</source><volume>4</volume>, <fpage>357</fpage>&#8211;<lpage>361</lpage><pub-id pub-id-type="doi">10.1021/acscentsci.7b00504</pub-id><pub-id pub-id-type="pmid">29632881</pub-id><pub-id pub-id-type="pmcid">PMC5879475</pub-id></mixed-citation></ref><ref id="BST-49-2411C37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kurbatova</surname>, <given-names>E.A.</given-names></string-name>, <string-name name-style="western"><surname>Akhmatova</surname>, <given-names>N.K.</given-names></string-name>, <string-name name-style="western"><surname>Zaytsev</surname>, <given-names>A.E.</given-names></string-name>, <string-name name-style="western"><surname>Akhmatova</surname>, <given-names>E.A.</given-names></string-name>, <string-name name-style="western"><surname>Egorova</surname>, <given-names>N.B.</given-names></string-name>, <string-name name-style="western"><surname>Yastrebova</surname>, <given-names>N.E.</given-names></string-name><etal>et al.</etal></person-group> (<year>2020</year>) <article-title>Higher cytokine and opsonizing antibody production induced by bovine serum albumin (BSA)-conjugated tetrasaccharide related to streptococcus pneumoniae type 3 capsular polysaccharide</article-title>. <source>Front. Immunol.</source><volume>11</volume>, <fpage>3165</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.578019</pub-id><pub-id pub-id-type="pmcid">PMC7746847</pub-id><pub-id pub-id-type="pmid">33343566</pub-id></mixed-citation></ref><ref id="BST-49-2411C38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kurbatova</surname>, <given-names>E.A.</given-names></string-name>, <string-name name-style="western"><surname>Akhmatova</surname>, <given-names>N.K.</given-names></string-name>, <string-name name-style="western"><surname>Akhmatova</surname>, <given-names>E.A.</given-names></string-name>, <string-name name-style="western"><surname>Egorova</surname>, <given-names>N.B.</given-names></string-name>, <string-name name-style="western"><surname>Yastrebova</surname>, <given-names>N.E.</given-names></string-name>, <string-name name-style="western"><surname>Sukhova E</surname>, <given-names>V.</given-names></string-name><etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Neoglycoconjugate of tetrasaccharide representing one repeating unit of the streptococcus pneumoniae type 14 capsular polysaccharide induces the production of opsonizing IgG1 antibodies and possesses the highest protective activity as compared to hexa- a</article-title>. <source>Front. Immunol.</source><volume>8</volume>, <fpage>659</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.00659</pub-id><pub-id pub-id-type="pmid">28626461</pub-id><pub-id pub-id-type="pmcid">PMC5454037</pub-id></mixed-citation></ref><ref id="BST-49-2411C39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kurbatova</surname>, <given-names>E.A.</given-names></string-name>, <string-name name-style="western"><surname>Yakovleva</surname>, <given-names>I.V.</given-names></string-name>, <string-name name-style="western"><surname>Akhmatova</surname>, <given-names>E.&#1040;</given-names></string-name>, <string-name name-style="western"><surname>Sukhova</surname>, <given-names>&#1045;V.</given-names></string-name>, <string-name name-style="western"><surname>Yashunsky</surname>, <given-names>D.V.</given-names></string-name>, <string-name name-style="western"><surname>Tsvetkov</surname>, <given-names>Y.E.</given-names></string-name><etal>et al.</etal></person-group> (<year>2019</year>) <article-title>Carbohydrate specificity and isotypes of monoclonal and polyclonal antibodies to conjugated tetrasaccharide, a synthetic analogue of repeating unit of capsular polysaccharide of streptococcus pneumoniae serotype 14</article-title>. <source>Bull. Exp. Biol. Med.</source><volume>166</volume>, <fpage>477</fpage>&#8211;<lpage>480</lpage><pub-id pub-id-type="doi">10.1007/s10517-019-04376-5</pub-id><pub-id pub-id-type="pmid">30788740</pub-id></mixed-citation></ref><ref id="BST-49-2411C40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xiong</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Qiao</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname>, <given-names>Z.</given-names></string-name> and <string-name name-style="western"><surname>Gu</surname>, <given-names>G.</given-names></string-name></person-group> (<year>2018</year>) <article-title>Synthesis and immunological studies of oligosaccharides that consist of the repeating unit of <italic toggle="yes">Streptococcus pneumoniae</italic> serotype 3 capsular polysaccharide</article-title>. <source>Chemistry</source><volume>24</volume>, <fpage>8205</fpage>&#8211;<lpage>8216</lpage><pub-id pub-id-type="doi">10.1002/chem.201800754</pub-id><pub-id pub-id-type="pmid">29528515</pub-id></mixed-citation></ref><ref id="BST-49-2411C41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Feng</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname>, <given-names>Z.</given-names></string-name> and <string-name name-style="western"><surname>Gu</surname>, <given-names>G.</given-names></string-name></person-group> (<year>2019</year>) <article-title>Semisynthetic glycoconjugate vaccines to elicit t cell-mediated immune responses and protection against <italic toggle="yes">Streptococcus pneumoniae</italic> serotype 3</article-title>. <source>ACS Infect. Dis.</source><volume>5</volume>, <fpage>1423</fpage>&#8211;<lpage>1432</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.9b00103</pub-id><pub-id pub-id-type="pmid">31126171</pub-id></mixed-citation></ref><ref id="BST-49-2411C42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Akhmatova</surname>, <given-names>N.K.</given-names></string-name>, <string-name name-style="western"><surname>Kurbatova</surname>, <given-names>E.A.</given-names></string-name>, <string-name name-style="western"><surname>Akhmatov</surname>, <given-names>E.A.</given-names></string-name>, <string-name name-style="western"><surname>Egorova</surname>, <given-names>N.B.</given-names></string-name>, <string-name name-style="western"><surname>Logunov</surname>, <given-names>D.Y.</given-names></string-name>, <string-name name-style="western"><surname>Gening</surname>, <given-names>M.L.</given-names></string-name><etal>et al.</etal></person-group> (<year>2016</year>) <article-title>The effect of a BSA conjugate of a synthetic hexasaccharide related to the fragment of capsular polysaccharide of <italic toggle="yes">Streptococcus pneumoniae</italic> type 14 on the activation of innate and adaptive immune responses</article-title>. <source>Front. Immunol.</source><volume>7</volume>, <fpage>248</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2016.00248</pub-id><pub-id pub-id-type="pmid">27446078</pub-id><pub-id pub-id-type="pmcid">PMC4919334</pub-id></mixed-citation></ref><ref id="BST-49-2411C43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morelli</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Fallarini</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Lombardi</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Colombo</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Lay</surname>, <given-names>L.</given-names></string-name> and <string-name name-style="western"><surname>Compostella</surname>, <given-names>F.</given-names></string-name></person-group> (<year>2018</year>) <article-title>Synthesis and biological evaluation of a trisaccharide repeating unit derivative of <italic toggle="yes">Streptococcus pneumoniae</italic> 19A capsular polysaccharide</article-title>. <source>Bioorg. Med. Chem.</source><volume>26</volume>, <fpage>5682</fpage>&#8211;<lpage>5690</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2018.10.016</pub-id><pub-id pub-id-type="pmid">30449426</pub-id></mixed-citation></ref><ref id="BST-49-2411C44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sanapala</surname>, <given-names>S.R.</given-names></string-name>, <string-name name-style="western"><surname>Seco</surname>, <given-names>B.M.S.</given-names></string-name>, <string-name name-style="western"><surname>Baek</surname>, <given-names>J.Y.</given-names></string-name>, <string-name name-style="western"><surname>Awan</surname>, <given-names>S.I.</given-names></string-name>, <string-name name-style="western"><surname>Pereira</surname>, <given-names>C.L.</given-names></string-name> and <string-name name-style="western"><surname>Seeberger</surname>, <given-names>P.H.</given-names></string-name></person-group> (<year>2020</year>) <article-title>Chimeric oligosaccharide conjugate induces opsonic antibodies against: Streptococcus pneumoniae serotypes 19A and 19F</article-title>. <source>Chem. Sci.</source><volume>11</volume>, <fpage>7401</fpage>&#8211;<lpage>7407</lpage><pub-id pub-id-type="doi">10.1039/D0SC02230F</pub-id><pub-id pub-id-type="pmid">34123020</pub-id><pub-id pub-id-type="pmcid">PMC8159444</pub-id></mixed-citation></ref><ref id="BST-49-2411C45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Prasanna</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Soulard</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Camberlein</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Ruffier</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Lambert</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Trottein</surname>, <given-names>F.</given-names></string-name><etal>et al.</etal></person-group> (<year>2019</year>) <article-title>Semisynthetic glycoconjugate based on dual role protein/PsaA as a pneumococcal vaccine</article-title>. <source>Eur. J. Pharm. Sci.</source><volume>129</volume>, <fpage>31</fpage>&#8211;<lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2018.12.013</pub-id><pub-id pub-id-type="pmid">30572107</pub-id></mixed-citation></ref><ref id="BST-49-2411C46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pillot</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Defontaine</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Fateh</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Lambert</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Prasanna</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Fanuel</surname>, <given-names>M.</given-names></string-name><etal>et al.</etal></person-group> (<year>2019</year>) <article-title>Site-specific conjugation for fully controlled glycoconjugate vaccine preparation</article-title>. <source>Front. Chem.</source><volume>7</volume>, <fpage>726</fpage><pub-id pub-id-type="doi">10.3389/fchem.2019.00726</pub-id><pub-id pub-id-type="pmid">31737603</pub-id><pub-id pub-id-type="pmcid">PMC6839274</pub-id></mixed-citation></ref><ref id="BST-49-2411C47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Seco</surname>, <given-names>B.M.S.</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname>, <given-names>F.-F.</given-names></string-name>, <string-name name-style="western"><surname>Grafm&#252;ller</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Kottari</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Pereira C</surname>, <given-names>L.</given-names></string-name> and <string-name name-style="western"><surname>Seeberger P</surname>, <given-names>H.</given-names></string-name></person-group> (<year>2020</year>) <article-title>Sequential linkage of carbohydrate antigens to mimic capsular polysaccharides: toward semisynthetic glycoconjugate vaccine candidates against <italic toggle="yes">Streptococcus pneumoniae</italic> serotype 14</article-title>. <source>ACS Chem. Biol.</source><volume>15</volume>, <fpage>2395</fpage>&#8211;<lpage>2405</lpage><pub-id pub-id-type="doi">10.1021/acschembio.0c00360</pub-id><pub-id pub-id-type="pmid">32835479</pub-id><pub-id pub-id-type="pmcid">PMC7506939</pub-id></mixed-citation></ref><ref id="BST-49-2411C48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Polonskaya</surname>, <given-names>Z.</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Sarkar</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Kain</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Comellas-Aragones</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>McKay</surname>, <given-names>C.S.</given-names></string-name><etal>et al.</etal></person-group> (<year>2017</year>) <article-title>T cells control the generation of nanomolar-affinity anti-glycan antibodies</article-title>. <source>J. Clin. Invest.</source><volume>127</volume>, <fpage>1491</fpage>&#8211;<lpage>1504</lpage><pub-id pub-id-type="doi">10.1172/JCI91192</pub-id><pub-id pub-id-type="pmid">28287405</pub-id><pub-id pub-id-type="pmcid">PMC5373877</pub-id></mixed-citation></ref><ref id="BST-49-2411C49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Walker</surname>, <given-names>M.J.</given-names></string-name>, <string-name name-style="western"><surname>Barnett</surname>, <given-names>T.C.</given-names></string-name>, <string-name name-style="western"><surname>McArthur</surname>, <given-names>J.D.</given-names></string-name>, <string-name name-style="western"><surname>Cole</surname>, <given-names>J.N.</given-names></string-name>, <string-name name-style="western"><surname>Gillen</surname>, <given-names>C.M.</given-names></string-name>, <string-name name-style="western"><surname>Henningham</surname>, <given-names>A.</given-names></string-name><etal>et al.</etal></person-group> (<year>2014</year>) <article-title>Disease manifestations and pathogenic mechanisms of group A streptococcus</article-title>. <source>Clin. Microbiol. Rev.</source><volume>27</volume>, <fpage>264</fpage>&#8211;<lpage>301</lpage><pub-id pub-id-type="doi">10.1128/CMR.00101-13</pub-id><pub-id pub-id-type="pmid">24696436</pub-id><pub-id pub-id-type="pmcid">PMC3993104</pub-id></mixed-citation></ref><ref id="BST-49-2411C50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Li</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname>, <given-names>Z.</given-names></string-name> and <string-name name-style="western"><surname>Gu</surname>, <given-names>G.</given-names></string-name></person-group> (<year>2019</year>) <article-title>Synthesis and immunological studies of group A streptococcus cell-wall oligosaccharide&#8211;streptococcal C5a peptidase conjugates as bivalent vaccines</article-title>. <source>Org. Chem. Front.</source><volume>6</volume>, <fpage>3589</fpage>&#8211;<lpage>3596</lpage><pub-id pub-id-type="doi">10.1039/C9QO00651F</pub-id></mixed-citation></ref><ref id="BST-49-2411C51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname>, <given-names>Z.</given-names></string-name> and <string-name name-style="western"><surname>Gu</surname>, <given-names>G.</given-names></string-name></person-group> (<year>2019</year>) <article-title>Group A streptococcus cell wall oligosaccharide-streptococcal C5a peptidase conjugates as effective antibacterial vaccines</article-title>. <source>ACS Infect. Dis.</source><volume>6</volume>, <fpage>281</fpage>&#8211;<lpage>290</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.9b00347</pub-id><pub-id pub-id-type="pmid">31872763</pub-id></mixed-citation></ref><ref id="BST-49-2411C52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pitirollo</surname>, <given-names>O.</given-names></string-name>, <string-name name-style="western"><surname>Micoli</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><surname>Necchi</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><surname>Mancini</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><surname>Carducci</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Adamo</surname>, <given-names>R.</given-names></string-name><etal>et al.</etal></person-group> (<year>2020</year>) <article-title>Gold nanoparticles morphology does not affect the multivalent presentation and antibody recognition of Group A Streptococcus synthetic oligorhamnans</article-title>. <source>Bioorg. Chem.</source><volume>99</volume>, <fpage>103815</fpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2020.103815</pub-id><pub-id pub-id-type="pmid">32289587</pub-id></mixed-citation></ref><ref id="BST-49-2411C53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liao</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname>, <given-names>Z.</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname>, <given-names>Z.</given-names></string-name> and <string-name name-style="western"><surname>Guo</surname>, <given-names>Z.</given-names></string-name></person-group> (<year>2019</year>) <article-title>Synthesis of a dimer of the repeating unit of type Ia group B streptococcus extracellular capsular polysaccharide and immunological evaluations of related protein conjugates</article-title>. <source>Org. Chem. Front. Int. J. Org. Chem.</source><volume>6</volume>, <fpage>2833</fpage>&#8211;<lpage>2838</lpage><pub-id pub-id-type="doi">10.1039/C9QO00486F</pub-id><pub-id pub-id-type="pmcid">PMC7144420</pub-id><pub-id pub-id-type="pmid">32274071</pub-id></mixed-citation></ref><ref id="BST-49-2411C54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cattaneo</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western"><surname>Carboni</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><surname>Oldrini</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>De Ricco</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Donadio</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Ros</surname>, <given-names>I.M.Y.</given-names></string-name><etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Synthesis of group B streptococcus type III polysaccharide fragments for evaluation of their interactions with monoclonal antibodies</article-title>. <source>Pure Appl. Chem.</source><volume>89</volume>, <fpage>855</fpage>&#8211;<lpage>875</lpage><pub-id pub-id-type="doi">10.1515/pac-2016-0918</pub-id></mixed-citation></ref><ref id="BST-49-2411C55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Oldrini</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>del Bino</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Arda</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Carboni</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><surname>Henriques</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Angiolini</surname>, <given-names>F.</given-names></string-name><etal>et al.</etal></person-group> (<year>2020</year>) <article-title>Structure-guided design of a group B streptococcus type III synthetic glycan&#8211;conjugate vaccine</article-title>. <source>Chemistry</source><volume>26</volume>, <fpage>6944</fpage><pub-id pub-id-type="doi">10.1002/chem.202002016</pub-id><pub-id pub-id-type="pmid">32390224</pub-id></mixed-citation></ref><ref id="BST-49-2411C56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carboni</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><surname>Adamo</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Fabbrini</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>De Ricco</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Cattaneo</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western"><surname>Brogioni</surname>, <given-names>B.</given-names></string-name><etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Structure of a protective epitope of group B streptococcus type III capsular polysaccharide</article-title>. <source>Proc. Natl Acad. Sci. U.S.A.</source><volume>114</volume>, <fpage>5017</fpage>&#8211;<lpage>5022</lpage><pub-id pub-id-type="doi">10.1073/pnas.1701885114</pub-id><pub-id pub-id-type="pmid">28439022</pub-id><pub-id pub-id-type="pmcid">PMC5441712</pub-id></mixed-citation></ref><ref id="BST-49-2411C57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Raabe</surname>, <given-names>V.N.</given-names></string-name> and <string-name name-style="western"><surname>Shane</surname>, <given-names>A.L.</given-names></string-name></person-group> (<year>2019</year>) <article-title>Group B streptococcus (Streptococcus agalactiae)</article-title>. <source>Microbiol. Spectr.</source><volume>7</volume>, <fpage>1</fpage>&#8211;<lpage>13</lpage><pub-id pub-id-type="doi">10.1128/microbiolspec.GPP3-0007-2018</pub-id><pub-id pub-id-type="pmcid">PMC6432937</pub-id><pub-id pub-id-type="pmid">30900541</pub-id></mixed-citation></ref><ref id="BST-49-2411C58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Del Bino</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Calloni</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western"><surname>Oldrini</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Raso</surname>, <given-names>M.M.</given-names></string-name>, <string-name name-style="western"><surname>Cuffaro</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Arda</surname>, <given-names>A.</given-names></string-name><etal>et al.</etal></person-group> (<year>2019</year>) <article-title>Regioselective glycosylation strategies for the synthesis of group Ia and Ib streptococcus related glycans enable elucidating unique conformations of the capsular polysaccharides</article-title>. <source>Chemistry</source><volume>25</volume>, <fpage>16277</fpage>&#8211;<lpage>16287</lpage><pub-id pub-id-type="doi">10.1002/chem.201903527</pub-id><pub-id pub-id-type="pmid">31506992</pub-id><pub-id pub-id-type="pmcid">PMC6972993</pub-id></mixed-citation></ref><ref id="BST-49-2411C59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shao</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Li</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname>, <given-names>Z.</given-names></string-name><etal>et al.</etal></person-group> (<year>2018</year>) <article-title>Chemical synthesis of the repeating unit of type II group B streptococcus capsular polysaccharide</article-title>. <source>J. Org. Chem.</source><volume>83</volume>, <fpage>5920</fpage>&#8211;<lpage>5930</lpage><pub-id pub-id-type="doi">10.1021/acs.joc.8b00396</pub-id><pub-id pub-id-type="pmid">29709182</pub-id></mixed-citation></ref><ref id="BST-49-2411C60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gao</surname>, <given-names>J.</given-names></string-name> and <string-name name-style="western"><surname>Guo</surname>, <given-names>Z.</given-names></string-name></person-group> (<year>2016</year>) <article-title>Chemical synthesis of the repeating unit of type V group B streptococcus capsular polysaccharide</article-title>. <source>Org. Lett.</source><volume>18</volume>, <fpage>5552</fpage>&#8211;<lpage>5555</lpage><pub-id pub-id-type="doi">10.1021/acs.orglett.6b02796</pub-id><pub-id pub-id-type="pmid">27809549</pub-id><pub-id pub-id-type="pmcid">PMC5645073</pub-id></mixed-citation></ref><ref id="BST-49-2411C61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Shao</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname>, <given-names>X.</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname>, <given-names>Z.</given-names></string-name> and <string-name name-style="western"><surname>Gao</surname>, <given-names>J.</given-names></string-name></person-group> (<year>2019</year>) <article-title>One-pot synthesis of the repeating unit of type VII group B streptococcus polysaccharide and the dimer</article-title>. <source>Org. Lett.</source><volume>21</volume>, <fpage>2374</fpage>&#8211;<lpage>2377</lpage><pub-id pub-id-type="doi">10.1021/acs.orglett.9b00653</pub-id><pub-id pub-id-type="pmid">30888190</pub-id></mixed-citation></ref><ref id="BST-49-2411C62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McCarthy</surname>, <given-names>P.C.</given-names></string-name>, <string-name name-style="western"><surname>Sharyan</surname>, <given-names>A.</given-names></string-name> and <string-name name-style="western"><surname>Sheikhi Moghaddam</surname>, <given-names>L.</given-names></string-name></person-group> (<year>2018</year>) <article-title>Meningococcal vaccines: current status and emerging strategies</article-title>. <source>Vaccines</source><volume>6</volume>, <fpage>12</fpage><pub-id pub-id-type="doi">10.3390/vaccines6010012</pub-id><pub-id pub-id-type="pmcid">PMC5874653</pub-id><pub-id pub-id-type="pmid">29495347</pub-id></mixed-citation></ref><ref id="BST-49-2411C63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Oldrini</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Fiebig</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Romano</surname>, <given-names>M.R.</given-names></string-name>, <string-name name-style="western"><surname>Proietti</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Berger</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Tontini</surname>, <given-names>M.</given-names></string-name><etal>et al.</etal></person-group> (<year>2018</year>) <article-title>Combined chemical synthesis and tailored enzymatic elongation provide fully synthetic and conjugation-ready <italic toggle="yes">Neisseria meningitidis</italic> Serogroup X vaccine antigens</article-title>. <source>ACS Chem. Biol.</source><volume>13</volume>, <fpage>984</fpage>&#8211;<lpage>994</lpage><pub-id pub-id-type="doi">10.1021/acschembio.7b01057</pub-id><pub-id pub-id-type="pmid">29481045</pub-id></mixed-citation></ref><ref id="BST-49-2411C64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Enotarpi</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Tontini</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Balocchi</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>van der Es</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Auberger</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Balducci</surname>, <given-names>E.</given-names></string-name><etal>et al.</etal></person-group> (<year>2020</year>) <article-title>A stabilized glycomimetic conjugate vaccine inducing protective antibodies against <italic toggle="yes">Neisseria meningitidis</italic> serogroup A</article-title>. <source>Nat. Commun.</source><volume>11</volume>, <fpage>4434</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-18279-x</pub-id><pub-id pub-id-type="pmid">32895393</pub-id><pub-id pub-id-type="pmcid">PMC7477203</pub-id></mixed-citation></ref><ref id="BST-49-2411C65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Harale</surname>, <given-names>K.R.</given-names></string-name>, <string-name name-style="western"><surname>Rout</surname>, <given-names>J.K.</given-names></string-name>, <string-name name-style="western"><surname>Chhikara</surname>, <given-names>M.K.</given-names></string-name>, <string-name name-style="western"><surname>Gill</surname>, <given-names>D.S.</given-names></string-name> and <string-name name-style="western"><surname>Misra</surname>, <given-names>A.K.</given-names></string-name></person-group> (<year>2017</year>) <article-title>Synthesis and immunochemical evaluation of a novel: <italic toggle="yes">Neisseria meningitidis</italic> serogroup A tetrasaccharide and its conjugate</article-title>. <source>Org. Chem. Front.</source><volume>4</volume>, <fpage>2348</fpage>&#8211;<lpage>2357</lpage><pub-id pub-id-type="doi">10.1039/C7QO00468K</pub-id></mixed-citation></ref><ref id="BST-49-2411C66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Henriques</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Dello Iacono</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Gimeno</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Biolchi</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Romano</surname>, <given-names>M.R.</given-names></string-name>, <string-name name-style="western"><surname>Arda</surname>, <given-names>A.</given-names></string-name><etal>et al.</etal></person-group> (<year>2020</year>) <article-title>Structure of a protective epitope reveals the importance of acetylation of <italic toggle="yes">Neisseria meningitidis</italic> serogroup A capsular polysaccharide</article-title>. <source>Proc. Natl Acad. Sci. U.S.A.</source><volume>117</volume>, <fpage>29795</fpage>&#8211;<lpage>29802</lpage><pub-id pub-id-type="doi">10.1073/pnas.2011385117</pub-id><pub-id pub-id-type="pmid">33158970</pub-id><pub-id pub-id-type="pmcid">PMC7703565</pub-id></mixed-citation></ref><ref id="BST-49-2411C67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dalal</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Rana</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Harale</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Hanif</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname>, <given-names>D.</given-names></string-name><etal>et al.</etal></person-group> (<year>2019</year>) <article-title>Development and pre-clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against <italic toggle="yes">Neisseria meningitidis</italic> serogroup C</article-title>. <source>Vaccine</source><volume>37</volume>, <fpage>5297</fpage>&#8211;<lpage>5306</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.07.053</pub-id><pub-id pub-id-type="pmid">31371227</pub-id></mixed-citation></ref><ref id="BST-49-2411C68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kong</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Vijayakrishnan</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Kowarik</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Park</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Zakharova</surname>, <given-names>A.N.</given-names></string-name>, <string-name name-style="western"><surname>Neiwert</surname>, <given-names>L.</given-names></string-name><etal>et al.</etal></person-group> (<year>2016</year>) <article-title>An antibacterial vaccination strategy based on a glycoconjugate containing the core lipopolysaccharide tetrasaccharide Hep2Kdo2</article-title>. <source>Nat. Chem.</source><volume>8</volume>, <fpage>242</fpage>&#8211;<lpage>249</lpage><pub-id pub-id-type="doi">10.1038/nchem.2432</pub-id><pub-id pub-id-type="pmid">26892556</pub-id></mixed-citation></ref><ref id="BST-49-2411C69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mani</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Wierzba</surname>, <given-names>T.</given-names></string-name> and <string-name name-style="western"><surname>Walker</surname>, <given-names>R.I.</given-names></string-name></person-group> (<year>2016</year>) <article-title>Status of vaccine research and development for Shigella</article-title>. <source>Vaccine</source><volume>34</volume>, <fpage>2887</fpage>&#8211;<lpage>2894</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.02.075</pub-id><pub-id pub-id-type="pmid">26979135</pub-id></mixed-citation></ref><ref id="BST-49-2411C70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>van der Put</surname>, <given-names>R.M.F.</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname>, <given-names>T.H.</given-names></string-name>, <string-name name-style="western"><surname>Guerreiro</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Thouron</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><surname>Hoogerhout</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Sansonetti</surname>, <given-names>P.J.</given-names></string-name><etal>et al.</etal></person-group> (<year>2016</year>) <article-title>A synthetic carbohydrate conjugate vaccine candidate against shigellosis: improved bioconjugation and impact of alum on immunogenicity</article-title>. <source>Bioconjug. Chem.</source><volume>27</volume>, <fpage>883</fpage>&#8211;<lpage>892</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.5b00617</pub-id><pub-id pub-id-type="pmid">26918643</pub-id></mixed-citation></ref><ref id="BST-49-2411C71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cohen</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Atsmon</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Artaud</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Meron-Sudai</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Gougeon</surname>, <given-names>M.-L.</given-names></string-name>, <string-name name-style="western"><surname>Bialik</surname>, <given-names>A.</given-names></string-name><etal>et al.</etal></person-group> (<year>2021</year>) <article-title>Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against <italic toggle="yes">shigella flexneri</italic> 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study</article-title>. <source>Lancet Infect. Dis.</source><volume>21</volume>, <fpage>546</fpage>&#8211;<lpage>58</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30488-6</pub-id><pub-id pub-id-type="pmid">33186516</pub-id></mixed-citation></ref><ref id="BST-49-2411C72"><label>72</label><mixed-citation publication-type="std"><comment>Anon. SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers [Internet]</comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.clinicaltrials.gov" ext-link-type="uri">www.clinicaltrials.gov</ext-link>. <comment>[cited 2021 Apr 12]. Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT02797236" ext-link-type="uri">https://www.clinicaltrials.gov/ct2/show/NCT02797236</ext-link></mixed-citation></ref><ref id="BST-49-2411C73"><label>73</label><mixed-citation publication-type="journal"><comment>Anon. Typhoid Vi Polysaccharide Vaccine Package insert [Internet]. 2014 [cited 2021 Apr 12]. p. 2&#8211;5. Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/media/75993/download" ext-link-type="uri">https://www.fda.gov/media/75993/download</ext-link></mixed-citation></ref><ref id="BST-49-2411C74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ni</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Springer</surname>, <given-names>M.J.</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Finger-Baker</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname>, <given-names>J.P.</given-names></string-name>, <string-name name-style="western"><surname>Cobb</surname>, <given-names>R.R.</given-names></string-name><etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Development of a synthetic Vi polysaccharide vaccine for typhoid fever</article-title>. <source>Vaccine</source><volume>35</volume>, <fpage>7121</fpage>&#8211;<lpage>7126</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.10.081</pub-id><pub-id pub-id-type="pmid">29150208</pub-id><pub-id pub-id-type="pmcid">PMC5754192</pub-id></mixed-citation></ref><ref id="BST-49-2411C75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Silva</surname>, <given-names>N.F.</given-names></string-name>, <string-name name-style="western"><surname>da Silva</surname>, <given-names>R.L.</given-names></string-name>, <string-name name-style="western"><surname>Almeida</surname>, <given-names>K.O.</given-names></string-name>, <string-name name-style="western"><surname>Nascimento-J&#250;nior</surname>, <given-names>A.E.S.D.</given-names></string-name>, <string-name name-style="western"><surname>Brasil</surname>, <given-names>D.D.S.B.</given-names></string-name>, <string-name name-style="western"><surname>Silva-J&#250;nior</surname>, <given-names>J.O.C.</given-names></string-name><etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Study of molecular interactions between chitosan and Vi antigen</article-title>. <source>J. Mol. Graph Model.</source><volume>72</volume>, <fpage>148</fpage>&#8211;<lpage>155</lpage><pub-id pub-id-type="doi">10.1016/j.jmgm.2016.12.015</pub-id><pub-id pub-id-type="pmid">28092833</pub-id></mixed-citation></ref><ref id="BST-49-2411C76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname>, <given-names>G.-L.</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname>, <given-names>W.</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname>, <given-names>D.-C.</given-names></string-name><etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Synthesis and antigenic evaluation of oligosaccharide mimics of Vi antigen from salmonella typhi</article-title>. <source>Chemistry</source><volume>23</volume>, <fpage>10670</fpage>&#8211;<lpage>10677</lpage><pub-id pub-id-type="doi">10.1002/chem.201702114</pub-id><pub-id pub-id-type="pmid">28622429</pub-id></mixed-citation></ref><ref id="BST-49-2411C77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Song</surname>, <given-names>C.</given-names></string-name> and <string-name name-style="western"><surname>Ma</surname>, <given-names>Y.</given-names></string-name></person-group> (<year>2018</year>) <article-title>Organic chemistry frontiers chemical synthesis and biological evaluation of penta- to octa- saccharide fragments of Vi polysaccharide from salmonella typhi</article-title>. <source>Org. Chem. Front.</source><volume>5</volume>, <fpage>2179</fpage>&#8211;<lpage>2188</lpage><pub-id pub-id-type="doi">10.1039/C8QO00471D</pub-id></mixed-citation></ref><ref id="BST-49-2411C78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huo</surname>, <given-names>C.-X.</given-names></string-name>, <string-name name-style="western"><surname>Dhara</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Baliban</surname>, <given-names>S.M.</given-names></string-name>, <string-name name-style="western"><surname>Tahmasebi Nick</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname>, <given-names>Z.</given-names></string-name>, <string-name name-style="western"><surname>Simon</surname>, <given-names>R.</given-names></string-name><etal>et al.</etal></person-group> (<year>2019</year>) <article-title>Synthetic and immunological studies of Salmonella Enteritidis O-antigen tetrasaccharides as potential anti-Salmonella vaccines</article-title>. <source>Chem. Commun.</source><volume>55</volume>, <fpage>4519</fpage>&#8211;<lpage>4522</lpage><pub-id pub-id-type="doi">10.1039/C8CC08622B</pub-id><pub-id pub-id-type="pmcid">PMC6525565</pub-id><pub-id pub-id-type="pmid">30924468</pub-id></mixed-citation></ref><ref id="BST-49-2411C79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dhara</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Baliban</surname>, <given-names>S.M.</given-names></string-name>, <string-name name-style="western"><surname>Huo</surname>, <given-names>C.-X.</given-names></string-name>, <string-name name-style="western"><surname>Rashidijahanabad</surname>, <given-names>Z.</given-names></string-name>, <string-name name-style="western"><surname>Sears</surname>, <given-names>K.T.</given-names></string-name>, <string-name name-style="western"><surname>Nick</surname>, <given-names>S.T.</given-names></string-name><etal>et al.</etal></person-group> (<year>2020</year>) <article-title>Syntheses of salmonella paratyphi A associated oligosaccharide antigens and development towards anti-paratyphoid fever vaccines</article-title>. <source>Chemistry</source><volume>26</volume>, <fpage>15953</fpage>&#8211;<lpage>15968</lpage><pub-id pub-id-type="doi">10.1002/chem.202002401</pub-id><pub-id pub-id-type="pmid">32578281</pub-id><pub-id pub-id-type="pmcid">PMC7722144</pub-id></mixed-citation></ref><ref id="BST-49-2411C80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Soliman</surname>, <given-names>S.E.</given-names></string-name> and <string-name name-style="western"><surname>Kov&#225;&#269;</surname>, <given-names>P.</given-names></string-name></person-group> (<year>2016</year>) <article-title>Total synthesis of the complete protective antigen of vibrio cholerae O139</article-title>. <source>Angew. Chem. Int. Ed. Engl.</source><volume>55</volume>, <fpage>12850</fpage>&#8211;<lpage>12853</lpage><pub-id pub-id-type="doi">10.1002/anie.201606116</pub-id><pub-id pub-id-type="pmid">27623688</pub-id><pub-id pub-id-type="pmcid">PMC5165651</pub-id></mixed-citation></ref><ref id="BST-49-2411C81"><label>81</label><mixed-citation publication-type="std"><comment>Anon. Shanchol Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine [Internet]. [cited 2021 Apr 12]. Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/immunization_standards/vaccine_quality/pq_250_cholera_1dose_shantha_insert.pdf" ext-link-type="uri">https://www.who.int/immunization_standards/vaccine_quality/pq_250_cholera_1dose_shantha_insert.pdf</ext-link></mixed-citation></ref><ref id="BST-49-2411C82"><label>82</label><mixed-citation publication-type="std"><comment>Anon. Euvichol (Oral Cholera Vaccine) Package insert [Internet]. [cited 2021 Apr 12]. Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/immunization_standards/vaccine_quality/pq_298_euvichol_1dose_eubiologics_PI.pdf?ua=1" ext-link-type="uri">https://www.who.int/immunization_standards/vaccine_quality/pq_298_euvichol_1dose_eubiologics_PI.pdf?ua=1</ext-link></mixed-citation></ref><ref id="BST-49-2411C83"><label>83</label><mixed-citation publication-type="std"><comment>Anon. Cholera - Vibrio Cholerae infection [Internet]. [cited 2021 Apr 12]. Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/cholera/vaccines.html" ext-link-type="uri">https://www.cdc.gov/cholera/vaccines.html</ext-link></mixed-citation></ref><ref id="BST-49-2411C84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lu</surname>, <given-names>X.</given-names></string-name>, <string-name name-style="western"><surname>Pfister</surname>, <given-names>H.B.</given-names></string-name>, <string-name name-style="western"><surname>Soliman</surname>, <given-names>S.E.</given-names></string-name> and <string-name name-style="western"><surname>Kov&#225;&#269;</surname>, <given-names>P.</given-names></string-name></person-group> (<year>2018</year>) <article-title>O-specific polysaccharide of <italic toggle="yes">Vibrio cholerae</italic> O139: improved synthesis and conjugation to BSA by squaric acid chemistry</article-title>. <source>Eur. J. Org. Chem.</source><volume>2018</volume>, <fpage>2944</fpage>&#8211;<lpage>2957</lpage><pub-id pub-id-type="doi">10.1002/ejoc.201800429</pub-id></mixed-citation></ref><ref id="BST-49-2411C85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pfister</surname>, <given-names>H.B.</given-names></string-name>, <string-name name-style="western"><surname>Kelly</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Qadri</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><surname>Ryan</surname>, <given-names>E.T.</given-names></string-name> and <string-name name-style="western"><surname>Kov&#225;&#269;</surname>, <given-names>P.</given-names></string-name></person-group> (<year>2019</year>) <article-title>Synthesis of glycocluster-containing conjugates for a vaccine against cholera</article-title>. <source>Org. Biomol. Chem.</source><volume>17</volume>, <fpage>4049</fpage>&#8211;<lpage>4060</lpage><pub-id pub-id-type="doi">10.1039/C9OB00368A</pub-id><pub-id pub-id-type="pmid">30950473</pub-id></mixed-citation></ref><ref id="BST-49-2411C86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Titball</surname>, <given-names>R.W.</given-names></string-name>, <string-name name-style="western"><surname>Burtnick</surname>, <given-names>M.N.</given-names></string-name>, <string-name name-style="western"><surname>Bancroft</surname>, <given-names>G.J.</given-names></string-name> and <string-name name-style="western"><surname>Brett</surname>, <given-names>P.</given-names></string-name></person-group> (<year>2017</year>) <article-title><italic toggle="yes">Burkholderia pseudomallei</italic> and <italic toggle="yes">Burkholderia mallei</italic> vaccines: are we close to clinical trials?</article-title><source>Vaccine</source><volume>35</volume>, <fpage>5981</fpage>&#8211;<lpage>5989</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.03.022</pub-id><pub-id pub-id-type="pmid">28336210</pub-id></mixed-citation></ref><ref id="BST-49-2411C87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Scott</surname>, <given-names>A.E.</given-names></string-name>, <string-name name-style="western"><surname>Christ</surname>, <given-names>W.J.</given-names></string-name>, <string-name name-style="western"><surname>George</surname>, <given-names>A.J.</given-names></string-name>, <string-name name-style="western"><surname>Stokes</surname>, <given-names>M.G.M.</given-names></string-name>, <string-name name-style="western"><surname>Lohman</surname>, <given-names>G.J.S.</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname>, <given-names>Y.</given-names></string-name><etal>et al.</etal></person-group> (<year>2016</year>) <article-title>Protection against experimental melioidosis with a synthetic manno-heptopyranose hexasaccharide glycoconjugate</article-title>. <source>Bioconjug. Chem.</source><volume>27</volume>, <fpage>1435</fpage>&#8211;<lpage>1446</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.5b00525</pub-id><pub-id pub-id-type="pmid">27124182</pub-id><pub-id pub-id-type="pmcid">PMC4911622</pub-id></mixed-citation></ref><ref id="BST-49-2411C88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tamigney Kenfack</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Mazur</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Nualnoi</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Shaffer</surname>, <given-names>T.L.</given-names></string-name>, <string-name name-style="western"><surname>Ngassimou</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Bl&#233;riot</surname>, <given-names>Y.</given-names></string-name><etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Deciphering minimal antigenic epitopes associated with <italic toggle="yes">Burkholderia pseudomallei</italic> and <italic toggle="yes">Burkholderia mallei</italic> lipopolysaccharide O-antigens</article-title>. <source>Nat. Commun.</source><volume>8</volume>, <fpage>115</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-00173-8</pub-id><pub-id pub-id-type="pmid">28740137</pub-id><pub-id pub-id-type="pmcid">PMC5524647</pub-id></mixed-citation></ref><ref id="BST-49-2411C89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Geng</surname>, <given-names>X.</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname>, <given-names>Z.</given-names></string-name> and <string-name name-style="western"><surname>Gu</surname>, <given-names>G.</given-names></string-name></person-group> (<year>2020</year>) <article-title>Synthesis of the oligosaccharides of <italic toggle="yes">Burkholderia pseudomallei</italic> and <italic toggle="yes">B. mallei</italic> capsular polysaccharide and preliminary immunological studies of their protein conjugates</article-title>. <source>J. Org. Chem.</source><volume>85</volume>, <fpage>2369</fpage>&#8211;<lpage>2384</lpage><pub-id pub-id-type="doi">10.1021/acs.joc.9b03085</pub-id><pub-id pub-id-type="pmid">31912729</pub-id></mixed-citation></ref><ref id="BST-49-2411C90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cloutier</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Delar</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Muru</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Ndong</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Hoyeck</surname>, <given-names>R.R.</given-names></string-name>, <string-name name-style="western"><surname>Kaewarpai</surname>, <given-names>T.</given-names></string-name><etal>et al.</etal></person-group> (<year>2019</year>) <article-title>Melioidosis patient serum-reactive synthetic tetrasaccharides bearing the predominant epitopes of <italic toggle="yes">Burkholderia pseudomallei</italic> and <italic toggle="yes">Burkholderia mallei</italic> O-antigens</article-title>. <source>Org. Biomol. Chem.</source><volume>17</volume>, <fpage>8878</fpage>&#8211;<lpage>8901</lpage><pub-id pub-id-type="doi">10.1039/C9OB01711A</pub-id><pub-id pub-id-type="pmid">31513223</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>